var title_f19_20_19776="Calculator: Alcohol consumption screening AUDIT questionnaire (Patient information)";
var content_f19_20_19776=[" <div id=\"disclaimer\">",
"  The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"  <a href=\"/home/terms-use\" target=\"_blank\">",
"   UpToDate Terms of Use",
"  </a>",
"  &copy;2013 UpToDate, Inc.",
" </div>",
" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"AlcoholScreen_form\" name=\"AlcoholScreen_form\" onreset=\"rrclr();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Alcohol consumption screening AUDIT questionnaire (Patient information)",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_main\">",
"     <div id=\"calc_input\">",
"      <center>",
"       <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           1) How often do you have a drink containing alcohol?",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc1\" onclick=\"AlcoholScreen_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Never (0 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc1\" onclick=\"AlcoholScreen_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Monthly or less (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc1\" onclick=\"AlcoholScreen_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           2 to 4 times a month (2 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc1\" onclick=\"AlcoholScreen_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           2 to 3 times a week (3 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc1\" onclick=\"AlcoholScreen_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           4 or more times a week (4 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           2) How many drinks containing alcohol do you have on a typical day when you are drinking?",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc2\" onclick=\"AlcoholScreen_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           1 or 2 (0 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc2\" onclick=\"AlcoholScreen_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           3 or 4 (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc2\" onclick=\"AlcoholScreen_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           5 or 6 (2 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc2\" onclick=\"AlcoholScreen_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           7 to 9 (3 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc2\" onclick=\"AlcoholScreen_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           10 or more (4 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           3) How often do you have 5 or more drinks on one occasion?",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc3\" onclick=\"AlcoholScreen_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Never (0 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc3\" onclick=\"AlcoholScreen_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Less than monthly (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc3\" onclick=\"AlcoholScreen_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Monthly (2 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc3\" onclick=\"AlcoholScreen_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Weekly (3 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc3\" onclick=\"AlcoholScreen_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Daily or almost daily (4 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           4) How often during the last year have you found that you were not able to stop drinking once you had started?",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc4\" onclick=\"AlcoholScreen_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Never (0 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc4\" onclick=\"AlcoholScreen_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Less than monthly (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc4\" onclick=\"AlcoholScreen_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Monthly (2 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc4\" onclick=\"AlcoholScreen_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Weekly (3 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc4\" onclick=\"AlcoholScreen_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Daily or almost daily (4 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           5) How often during the last year have you failed to do what was normally expected of you because of drinking?",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc5\" onclick=\"AlcoholScreen_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Never (0 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc5\" onclick=\"AlcoholScreen_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Less than monthly (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc5\" onclick=\"AlcoholScreen_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Monthly (2 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc5\" onclick=\"AlcoholScreen_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Weekly (3 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc5\" onclick=\"AlcoholScreen_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Daily or almost daily (4 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           6) How often during the last year have you needed a first drink in the morning to get yourself going after a heavy drinking session?",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc6\" onclick=\"AlcoholScreen_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Never (0 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc6\" onclick=\"AlcoholScreen_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Less than monthly (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc6\" onclick=\"AlcoholScreen_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Monthly (2 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc6\" onclick=\"AlcoholScreen_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Weekly (3 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc6\" onclick=\"AlcoholScreen_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Daily or almost daily (4 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           7) How often during the last year have you had a feeling of guilt or remorse after drinking?",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc7\" onclick=\"AlcoholScreen_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Never (0 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc7\" onclick=\"AlcoholScreen_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Less than monthly (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc7\" onclick=\"AlcoholScreen_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Monthly (2 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc7\" onclick=\"AlcoholScreen_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Weekly (3 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc7\" onclick=\"AlcoholScreen_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Daily or almost daily (4 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           8) How often during the last year have you been unable to remember what happened the night before because you had been drinking?",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc8\" onclick=\"AlcoholScreen_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Never (0 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc8\" onclick=\"AlcoholScreen_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Less than monthly (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc8\" onclick=\"AlcoholScreen_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Monthly (2 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc8\" onclick=\"AlcoholScreen_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Weekly (3 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc8\" onclick=\"AlcoholScreen_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Daily or almost daily (4 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           9) Have you or someone else been injured as a result of your drinking?",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc9\" onclick=\"AlcoholScreen_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           No (0 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc9\" onclick=\"AlcoholScreen_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Yes, but not in the last year (2 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc9\" onclick=\"AlcoholScreen_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Yes, during the last year (4 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           10) Has a relative, a friend, a doctor or another health worker been concerned about your drinking or suggested you cut down?",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc10\" onclick=\"AlcoholScreen_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           No (0 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc10\" onclick=\"AlcoholScreen_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Yes, but not in the last year (2 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc10\" onclick=\"AlcoholScreen_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Yes, during the last year (4 points)",
"          </span>",
"         </td>",
"        </tr>",
"       </table>",
"      </center>",
"     </div>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <div id=\"calc_result\">",
"      <span class=\"medCalcFontCCTabBold\">",
"       Total Criteria Point Count:",
"      </span>",
"      <input name=\"cctotal\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"      <center>",
"       <input name=\"reset\" type=\"reset\" value=\"Reset Form\"/>",
"      </center>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"      <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"70%\">",
"       <tr>",
"        <td bgcolor=\"#eeeeee\" width=\"1%\">",
"         <br/>",
"        </td>",
"        <td align=\"left\" bgcolor=\"#eeeeee\">",
"         <span class=\"medCalcFontTitleBox\">",
"          Alcohol Screen Score",
"         </span>",
"        </td>",
"       </tr>",
"      </table>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"      <center>",
"       <table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" summary=\"RRTable\">",
"        <tr id=\"rr1_1\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           0-7 Points:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           Low risk",
"          </span>",
"         </td>",
"        </tr>",
"        <tr id=\"rr1_2\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           8-15 Points:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           Medium risk",
"          </span>",
"         </td>",
"        </tr>",
"        <tr id=\"rr1_3\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           16-19 Points:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           High risk",
"          </span>",
"         </td>",
"        </tr>",
"        <tr id=\"rr1_4\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           20-40 Points:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           Addiction likely",
"          </span>",
"         </td>",
"        </tr>",
"       </table>",
"      </center>",
"     </div>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_hints\">",
"     <span class=\"medCalcFontOneBold\">",
"      Notes",
"     </span>",
"     <ul class=\"medCalcFontOne\">",
"      <li>",
"       <b>",
"        Low Risk",
"       </b>",
"       (0-7 points) You probably do not have a problem with alcohol. Continue drinking in moderation or not at all.",
"      </li>",
"      <li>",
"       <b>",
"        Medium Risk",
"       </b>",
"       (8-15 points) You may drink too much on occasion. This may put you or others at risk. Try to cut down on alcohol or stop drinking completely.",
"      </li>",
"      <li>",
"       <b>",
"        High Risk",
"       </b>",
"       (16-19 points) Your drinking could lead to harm, if it hasn't already. It's important that you cut down on alcohol or stop drinking completely. Ask your doctor or nurse for advice on how best to cut down.",
"      </li>",
"      <li>",
"       <b>",
"        Addiction Likely",
"       </b>",
"       (20+ points) It is likely that your drinking is causing harm. Speak to your doctor or nurse, or an addiction specialist. Ask about medications and counseling that can help you stop drinking. If you are dependent on alcohol, do not stop drinking without the help of a healthcare professional.",
"      </li>",
"     </ul>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_refs\">",
"     <span class=\"medCalcFontRef\">",
"      <b>",
"       References",
"      </b>",
"     </span>",
"     <ol>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Reproduced with permission from: Babor, TF, Higgins-Biddle, JC, Saunders, JB, Monteiro, MG. The Alcohol Use Disorder  Identification Test: Guidelines for Use in Primary Care, Second Edition. World Health Organization, 2001. Available at:  file://whqlibdoc.who.int/hq/2001/who_msd_msb_01.6a.pdf.",
"       </span>",
"      </li>",
"     </ol>",
"    </div>",
"   </form>",
"   <script language=\"JavaScript1.1\" type=\"text/javascript\">",
"    &lt;!--",
"",
";",
"AlcoholScreen_fx();",
"//--&gt;",
"   </script>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_20_19776=[" ",
"",
"var calctxt = '';",
"var xmltxt = '';",
"var htmtxt = '';",
"",
"",
"function AlcoholScreen_fx() {",
"with(document.AlcoholScreen_form){",
"",
"Score = 0.0;",
"doCalc = true;",
"",
"if (cc1[0].checked){",
"Score = Score + 0;",
"}",
"if (cc1[1].checked){",
"Score = Score + 1;",
"}",
"if (cc1[2].checked){",
"Score = Score + 2;",
"}",
"if (cc1[3].checked){",
"Score = Score + 3;",
"}",
"if (cc1[4].checked){",
"Score = Score + 4;",
"}",
"if (cc2[0].checked){",
"Score = Score + 0;",
"}",
"if (cc2[1].checked){",
"Score = Score + 1;",
"}",
"if (cc2[2].checked){",
"Score = Score + 2;",
"}",
"if (cc2[3].checked){",
"Score = Score + 3;",
"}",
"if (cc2[4].checked){",
"Score = Score + 4;",
"}",
"if (cc3[0].checked){",
"Score = Score + 0;",
"}",
"if (cc3[1].checked){",
"Score = Score + 1;",
"}",
"if (cc3[2].checked){",
"Score = Score + 2;",
"}",
"if (cc3[3].checked){",
"Score = Score + 3;",
"}",
"if (cc3[4].checked){",
"Score = Score + 4;",
"}",
"if (cc4[0].checked){",
"Score = Score + 0;",
"}",
"if (cc4[1].checked){",
"Score = Score + 1;",
"}",
"if (cc4[2].checked){",
"Score = Score + 2;",
"}",
"if (cc4[3].checked){",
"Score = Score + 3;",
"}",
"if (cc4[4].checked){",
"Score = Score + 4;",
"}",
"if (cc5[0].checked){",
"Score = Score + 0;",
"}",
"if (cc5[1].checked){",
"Score = Score + 1;",
"}",
"if (cc5[2].checked){",
"Score = Score + 2;",
"}",
"if (cc5[3].checked){",
"Score = Score + 3;",
"}",
"if (cc5[4].checked){",
"Score = Score + 4;",
"}",
"if (cc6[0].checked){",
"Score = Score + 0;",
"}",
"if (cc6[1].checked){",
"Score = Score + 1;",
"}",
"if (cc6[2].checked){",
"Score = Score + 2;",
"}",
"if (cc6[3].checked){",
"Score = Score + 3;",
"}",
"if (cc6[4].checked){",
"Score = Score + 4;",
"}",
"if (cc7[0].checked){",
"Score = Score + 0;",
"}",
"if (cc7[1].checked){",
"Score = Score + 1;",
"}",
"if (cc7[2].checked){",
"Score = Score + 2;",
"}",
"if (cc7[3].checked){",
"Score = Score + 3;",
"}",
"if (cc7[4].checked){",
"Score = Score + 4;",
"}",
"if (cc8[0].checked){",
"Score = Score + 0;",
"}",
"if (cc8[1].checked){",
"Score = Score + 1;",
"}",
"if (cc8[2].checked){",
"Score = Score + 2;",
"}",
"if (cc8[3].checked){",
"Score = Score + 3;",
"}",
"if (cc8[4].checked){",
"Score = Score + 4;",
"}",
"if (cc9[0].checked){",
"Score = Score + 0;",
"}",
"if (cc9[1].checked){",
"Score = Score + 2;",
"}",
"if (cc9[2].checked){",
"Score = Score + 4;",
"}",
"if (cc10[0].checked){",
"Score = Score + 0;",
"}",
"if (cc10[1].checked){",
"Score = Score + 2;",
"}",
"if (cc10[2].checked){",
"Score = Score + 4;",
"}",
"cctotal.value = Score;",
"",
"if (doCalc){",
"rrclr();",
"if ((Score >= 0) && (Score <= 7)){ document.getElementById('rr1_1').bgColor = '#cccccc';",
"}",
"if ((Score >= 8) && (Score <= 15)){ document.getElementById('rr1_2').bgColor = '#cccccc';",
"}",
"if ((Score >= 16) && (Score <= 19)){ document.getElementById('rr1_3').bgColor = '#cccccc';",
"}",
"if ((Score >= 20) && (Score <= 40)){ document.getElementById('rr1_4').bgColor = '#cccccc';",
"}",
"",
"}",
"}",
"}",
"",
"",
"",
"",
"function rrclr(){",
"document.getElementById('rr1_1').bgColor = \"\";",
"document.getElementById('rr1_2').bgColor = \"\";",
"document.getElementById('rr1_3').bgColor = \"\";",
"document.getElementById('rr1_4').bgColor = \"\";",
"}",
"",
"",
""].join("\n");
var outline_f19_20_19776=null;
var title_f19_20_19777="Left upper lobe atelectasis B";
var content_f19_20_19777=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F63366&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F63366&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 597px\">",
"   <div class=\"ttl\">",
"    Resolving left upper lobe atelectasis in a child with cystic fibrosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 577px; height: 308px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Follow-up radiographs obtained four days later demonstrate partial reexpansion of the left upper lobe, with residual posterior segment and ligular atelectasis. The opacity on the lateral film represents \"plate-like\" atelectasis of the posterior left upper lobe.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_20_19777=[""].join("\n");
var outline_f19_20_19777=null;
var title_f19_20_19778="Incisions for lateral neck dissection";
var content_f19_20_19778=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F88332&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F88332&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 561px\">",
"   <div class=\"ttl\">",
"    Incisions for lateral neck dissection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 541px; height: 558px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Levels III and IV can usually be reached through a standard thyroidectomy incision or a slight extension of that traditional incision to the side of the neck dissection (A).&nbsp; For a more comprehensive neck dissection, the incision must be extended into the lateral neck, either along a skin crease (B) or with a superior &ldquo;hockey-stick&rdquo; extension either anterior or posterior to the sternocleidomastoid (C).&nbsp; Instead of using the superior extension of the main incision, some surgeons advocate using incision A and making a second counter incision high within the neck (also within a neck crease) in order to access level II adequately (D).&nbsp;",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_20_19778=[""].join("\n");
var outline_f19_20_19778=null;
var title_f19_20_19779="Complete fracture reduction B";
var content_f19_20_19779=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F75892&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F75892&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Complete fracture reduction: Realignment",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 418px; height: 454px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panels A and B) Once length has been reestablished, the distal fragment is flexed into the correct position. Alignment is checked by determining the position of the fragments with the thumb and forefingers of each hand.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Waters PM, Mih AD. Fractures of the distal radius and ulna. In: Rockwood and Wilkins' Fractures in Children, 6th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_20_19779=[""].join("\n");
var outline_f19_20_19779=null;
var title_f19_20_19780="Investigational methods in the diagnosis of acute renal allograft rejection";
var content_f19_20_19780=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Investigational methods in the diagnosis of acute renal allograft rejection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/20/19780/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/20/19780/contributors\">",
"     W James Chon, MD, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/20/19780/contributors\">",
"     Daniel C Brennan, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/20/19780/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/20/19780/contributors\">",
"     Barbara Murphy, MB, BAO, BCh, FRCPI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/20/19780/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/20/19780/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/20/19780/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The introduction of potent immunosuppressive drugs in the past three decades has led to a dramatic reduction in the incidence of acute rejection in kidney transplant recipients. At the present time, renal allograft biopsy with conventional histologic evaluation remains the gold standard for diagnosing acute rejection among patients with a deterioration in kidney function as detected by measuring serum creatinine levels. However, the lack of additional markers of rejection makes it difficult to optimize anti-rejection therapy for transplant recipients.",
"   </p>",
"   <p>",
"    The evaluation of methods other than conventional renal biopsy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    measurement of the serum creatinine to help diagnosis acute kidney rejection has been the focus of a large number of investigators. This topic review will discuss some of the methods undergoing investigation for the diagnosis of acute rejection. The clinical diagnosis of rejection is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/13/12505?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute renal allograft rejection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SERUM OR URINARY MEASUREMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measuring the levels of urinary or circulating proteins and cytokines, circulating soluble interleukin-2 (IL-2) receptor, the urinary concentration of soluble adhesion molecules, or cellular activation with urinary flow cytometry may be helpful in diagnosing acute allograft rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19780/abstract/1-9\">",
"     1-9",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The urinary concentration of the mRNAs for perforin, granzyme B, and cyclophilin B as determined by quantitative polymerase chain reaction was assessed among 22 renal allograft recipients with biopsy-confirmed acute rejection and 63 recipients without any evidence of rejection [",
"      <a class=\"abstract\" href=\"UTD.htm?19/20/19780/abstract/7\">",
"       7",
"      </a>",
"      ]. A threshold level of 0.9 femtograms (fg) of perforin mRNA per microgram of total RNA was associated with a sensitivity and specificity of 83 percent for acute rejection, while a level of 0.4 fg of granzyme B RNA per microgram of total RNA resulted in a sensitivity and specificity of 79 and 77 percent, respectively.",
"     </li>",
"     <li>",
"      Another report analyzed the correlation between the expression of cytokines within peripheral blood leukocytes, and the presence or absence of rejection [",
"      <a class=\"abstract\" href=\"UTD.htm?19/20/19780/abstract/8\">",
"       8",
"      </a>",
"      ]. Enhanced expression of any two genes among perforin, granzyme B, and Fas ligand (as detected by reverse transcriptase polymerase chain reaction) was associated with 100 percent positive predictive value for the diagnosis of rejection, while one or no elevated values had a 95 percent negative predictive value for rejection.",
"     </li>",
"     <li>",
"      FOXP3+ is a X-linked forkhead transcription factor expressed on regulatory T lymphocytes. Using quantitative PCR, urinary cell mRNA levels of various molecules were assessed among 36, 18, and 29 patients with acute rejection, chronic allograft nephropathy, and normal biopsy results, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?19/20/19780/abstract/10\">",
"       10",
"      </a>",
"      ]. Acute renal allograft rejection correlated with increased urinary cell mRNA levels of FOXP3, CD25, CD3epsilon, and perforin. High levels of FOXP3 also predicted successful reversal of acute rejection, while low levels identified those at increased risk of eventual allograft failure after the rejection episode.",
"     </li>",
"     <li>",
"      TIM-3 (T cell immunoglobulin domain, mucin domain) is a type I membrane protein expressed on Th1 differentiated cells and its measurement in urine, blood, or tissue has been quantified in the setting of renal allograft dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?19/20/19780/abstract/11,12\">",
"       11,12",
"      </a>",
"      ]. In one study, urine samples from 60 consecutive renal transplant recipients who were undergoing allograft biopsy were collected and the mRNA encoding for TIM-3 was quantified using real time RT-PCR. TIM-3 was highly expressed in patients with acute rejection compared to those without acute renal rejection and with stable allograft function [",
"      <a class=\"abstract\" href=\"UTD.htm?19/20/19780/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Interleukin-6 (IL-6) may be a potential biomarker for acute rejection. In an observational study of 32 patients who presented with acute graft dysfunction, of six tested cytokines (including IL-1beta, IL-6, TNF-alpha, IL-4, GM-CSF and MCP-1), IL-6 best predicted acute rejection [",
"      <a class=\"abstract\" href=\"UTD.htm?19/20/19780/abstract/9\">",
"       9",
"      </a>",
"      ]. Among a validation cohort of 32 additional patients, using a prespecified IL-6 cutoff level of 85",
"      <span class=\"nowrap\">",
"       pg/mL,",
"      </span>",
"      IL-6 assay had a sensitivity of 92 and specificity of 63 percent for the diagnosis of acute rejection. These results need to be confirmed in a larger prospective trial. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     ImmunoKnow assay",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ImmuKnow assay is an FDA-approved test intended to estimate the net state of immune system in immunocompromised patients. It measures the ability of CD4 cells to respond to mitogenic stimulation by phytohemagglutinin-L in vitro by quantifying the amount of ATP produced and released from these cells following stimulation.",
"   </p>",
"   <p>",
"    At the present time, there is no consensus on the utility of these tests other than in the research setting. Nonetheless, these assays may prove helpful both for diagnostic purposes and for monitoring the response to antirejection therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     KIDNEY BIOPSY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The application of modern biologic techniques to conventional renal biopsy may provide another way to enhance the accuracy of diagnosis of acute rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19780/abstract/8,13-19\">",
"     8,13-19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, renal allograft biopsies from patients with acute rejection were compared to those with subclinical rejection, and no rejection. Both histological and transcriptional analysis showed that a renal allograft with acute rejection was associated with upregulation of transcription factor T-bet, FAS ligand, and CD152 [",
"      <a class=\"abstract\" href=\"UTD.htm?19/20/19780/abstract/18\">",
"       18",
"      </a>",
"      ]. This pattern was not found in biopsies from those with subclinical rejection and no rejection, or from non-transplanted kidneys.",
"     </li>",
"     <li>",
"      Another study quantitatively measured the renal allograft expression of various cytokines and cellular markers of immune activation using reverse transcriptase polymerase chain reaction (PCR) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/20/19780/abstract/14\">",
"       14",
"      </a>",
"      ]. Among 60 renal allograft biopsies, enhanced expression of IL-7, IL-10, IL-15, Fas ligand, perforin, and granzyme B was significantly associated with acute rejection as determined by histology (Banff criteria) and the response to therapy. Combined analysis of perforin, granzyme B, and Fas ligand had a 100 percent sensitivity and specificity for acute rejection. Similar findings were observed in another study of 43 human renal allograft biopsies [",
"      <a class=\"abstract\" href=\"UTD.htm?19/20/19780/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Two studies used FoxP3 expression to predict outcome of the renal allograft. In a study of 37 cases of subclinical rejection, the presence of FoxP3+ Tregs correctly predicted better graft function two and three years after transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?19/20/19780/abstract/20\">",
"       20",
"      </a>",
"      ]. In 46 cases of borderline change on renal allograft biopsy, measurement of FoxP3+ mRNA level ratio (compared to GAPDH) was a predictor of good prognosis when a cutoff value of &gt;0.0115 was used [",
"      <a class=\"abstract\" href=\"UTD.htm?19/20/19780/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      DNA microarray profiling is a powerful technology that enables simultaneous analysis of tens of thousands of genes. One study looked at the gene expression patterns of biopsy samples in children with acute renal allograft rejection, which showed substantial molecular heterogeneity [",
"      <a class=\"abstract\" href=\"UTD.htm?19/20/19780/abstract/15\">",
"       15",
"      </a>",
"      ]. Immunohistochemical staining demonstrated a substantial association between dense CD20 positive B cell infiltrates and glucocorticoid-resistant rejection.",
"     </li>",
"     <li>",
"      Another study used DNA microarrays to determine gene expression profiles for kidney biopsies and peripheral blood lymphocytes in transplant recipients with normal function, acute rejection, or allograft dysfunction without acute rejection. They identified distinct gene expression signatures for the different groups [",
"      <a class=\"abstract\" href=\"UTD.htm?19/20/19780/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Interpretation of these studies is unclear since none included patients with either bacterial or viral infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A renal allograft biopsy with conventional histologic evaluation is the gold standard for diagnosing acute rejection. The evaluation of other methods to help diagnosis acute kidney rejection is the focus of a large number of investigators. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Measuring the levels of urinary or circulating proteins and cytokines, circulating soluble interleukin-2 (IL-2) receptor, the urinary concentration of soluble adhesion molecules, or cellular activation with urinary flow cytometry may be helpful in diagnosing acute allograft rejection. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Serum or urinary measurements'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The application of modern biologic techniques to conventional renal biopsy may provide another way to enhance the accuracy of diagnosis of acute rejection. Some techniques include DNA microarrays and PCR analysis. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Kidney biopsy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19780/abstract/1\">",
"      Simpson MA, Madras PN, Cornaby AJ, et al. Sequential determinations of urinary cytology and plasma and urinary lymphokines in the management of renal allograft recipients. Transplantation 1989; 47:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19780/abstract/2\">",
"      Yoshimura N, Oka T, Kahan BD. Sequential determinations of serum interleukin 6 levels as an immunodiagnostic tool to differentiate rejection from nephrotoxicity in renal allograft recipients. Transplantation 1991; 51:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19780/abstract/3\">",
"      Forsythe JL, Shenton BK, Parrot NR, et al. Plasma interleukin 2 receptor levels in renal allograft dysfunction. Transplantation 1989; 48:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19780/abstract/4\">",
"      Bechtel U, Scheuer R, Landgraf R, et al. Assessment of soluble adhesion molecules (sICAM-1, sVCAM-1, sELAM-1) and complement cleavage products (sC4d, sC5b-9) in urine. Clinical monitoring of renal allograft recipients. Transplantation 1994; 58:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19780/abstract/5\">",
"      Casiraghi F, Ruggenenti P, Noris M, et al. Sequential monitoring of urine-soluble interleukin 2 receptor and interleukin 6 predicts acute rejection of human renal allografts before clinical or laboratory signs of renal dysfunction. Transplantation 1997; 63:1508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19780/abstract/6\">",
"      Roberti I, Panico M, Reisman L. Urine flow cytometry as a tool to differentiate acute allograft rejection from other causes of acute renal graft dysfunction. Transplantation 1997; 64:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19780/abstract/7\">",
"      Li B, Hartono C, Ding R, et al. Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine. N Engl J Med 2001; 344:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19780/abstract/8\">",
"      Vasconcellos LM, Schachter AD, Zheng XX, et al. Cytotoxic lymphocyte gene expression in peripheral blood leukocytes correlates with rejecting renal allografts. Transplantation 1998; 66:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19780/abstract/9\">",
"      De Serres SA, Mfarrej BG, Grafals M, et al. Derivation and validation of a cytokine-based assay to screen for acute rejection in renal transplant recipients. Clin J Am Soc Nephrol 2012; 7:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19780/abstract/10\">",
"      Muthukumar T, Dadhania D, Ding R, et al. Messenger RNA for FOXP3 in the urine of renal-allograft recipients. N Engl J Med 2005; 353:2342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19780/abstract/11\">",
"      Renesto PG, Ponciano VC, Cenedeze MA, et al. High expression of Tim-3 mRNA in urinary cells from kidney transplant recipients with acute rejection. Am J Transplant 2007; 7:1661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19780/abstract/12\">",
"      Manfro RC, Aquino-Dias EC, Joelsons G, et al. Noninvasive Tim-3 messenger RNA evaluation in renal transplant recipients with graft dysfunction. Transplantation 2008; 86:1869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19780/abstract/13\">",
"      Suthanthiran M. Acute rejection of renal allografts: mechanistic insights and therapeutic options. Kidney Int 1997; 51:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19780/abstract/14\">",
"      Strehlau J, Pavlakis M, Lipman M, et al. Quantitative detection of immune activation transcripts as a diagnostic tool in kidney transplantation. Proc Natl Acad Sci U S A 1997; 94:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19780/abstract/15\">",
"      Sarwal M, Chua MS, Kambham N, et al. Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N Engl J Med 2003; 349:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19780/abstract/16\">",
"      Schaub S, Rush D, Wilkins J, et al. Proteomic-based detection of urine proteins associated with acute renal allograft rejection. J Am Soc Nephrol 2004; 15:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19780/abstract/17\">",
"      Desvaux D, Schwarzinger M, Pastural M, et al. Molecular diagnosis of renal-allograft rejection: correlation with histopathologic evaluation and antirejection-therapy resistance. Transplantation 2004; 78:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19780/abstract/18\">",
"      Hoffmann SC, Hale DA, Kleiner DE, et al. Functionally significant renal allograft rejection is defined by transcriptional criteria. Am J Transplant 2005; 5:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19780/abstract/19\">",
"      Strom TB, Suthanthiran M. Transcriptional profiling to assess the clinical status of kidney transplants. Nat Clin Pract Nephrol 2006; 2:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19780/abstract/20\">",
"      Bestard O, Cruzado JM, Rama I, et al. Presence of FoxP3+ regulatory T Cells predicts outcome of subclinical rejection of renal allografts. J Am Soc Nephrol 2008; 19:2020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19780/abstract/21\">",
"      Mansour H, Homs S, Desvaux D, et al. Intragraft levels of Foxp3 mRNA predict progression in renal transplants with borderline change. J Am Soc Nephrol 2008; 19:2277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19780/abstract/22\">",
"      Flechner SM, Kurian SM, Head SR, et al. Kidney transplant rejection and tissue injury by gene profiling of biopsies and peripheral blood lymphocytes. Am J Transplant 2004; 4:1475.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7325 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-199.231.185.123-2EEB765D3A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_20_19780=[""].join("\n");
var outline_f19_20_19780=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SERUM OR URINARY MEASUREMENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ImmunoKnow assay",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      KIDNEY BIOPSY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/13/12505?source=related_link\">",
"      Clinical manifestations and diagnosis of acute renal allograft rejection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_20_19781="Retained surgical sponge on FDG-PET";
var content_f19_20_19781=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F50655&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F50655&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 604px\">",
"   <div class=\"ttl\">",
"    Retained surgical sponge on FDG-PET*",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 584px; height: 375px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Intraabdominal gossypiboma in a 42-year-old woman who had undergone cesarean sections twice previously.",
"    <br>",
"     (A) Transaxial positive emission tomography (PET) image with uneven fluorodeoxyglucose (FDG) uptake at the rim of a mass.",
"     <br>",
"      (B) Coronal reconstruction showing the retained sponge (arrow) on PET computed tomography (CT).",
"      <br>",
"       (C) Excised surgical specimen showing retained sponge in situ.",
"       <div class=\"footnotes\">",
"        * FDG-PET: fluorodeoxyglucose positive emission tomography.",
"       </div>",
"       <div class=\"reference\">",
"        Reproduced with permission from: Yuh-Feng T, Chin-Chu W, Cheng-Tau S, Min-Tsung T. FDG PET CT Features of an intraabdominal gossypiboma. Clin Nucl Med 2005; 30:561. Copyright &copy; 2005 Lippincott Williams &amp; Wilkins.",
"       </div>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_20_19781=[""].join("\n");
var outline_f19_20_19781=null;
var title_f19_20_19782="Central neck dissection";
var content_f19_20_19782=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F67441&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F67441&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lymphadenectomy for thyroid cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 442px; height: 680px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The extent of lymphadenectomy is based on the type of thyroid malignancy and the risk for lymph node metastasis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     By permission of Mayo Foundation for Medical Education and Research. All rights reserved. Copyright &copy; 2010.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_20_19782=[""].join("\n");
var outline_f19_20_19782=null;
var title_f19_20_19783="Enalaprilat (intravenous): Pediatric drug information";
var content_f19_20_19783=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Enalaprilat (intravenous): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?20/22/20839?source=see_link\">",
"    see \"Enalaprilat (intravenous): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?17/24/17796?source=see_link\">",
"    see \"Enalaprilat (intravenous): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F13657030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F13655454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Vasotec&reg; I.V",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F13732620\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Angiotensin-Converting Enzyme (ACE) Inhibitor",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F13732720\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use lower listed initial dose in patients with hyponatremia, hypovolemia, severe CHF, decreased renal function, or in those receiving diuretics",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     I.V.: 5-10",
"     <b>",
"      mcg",
"     </b>",
"     /kg/dose every 8-24 hours as determined by clinical response (eg, blood pressure readings); monitor patients carefully; some patients may require higher doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Use in neonates with GFR &lt;30 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     is not recommended; no dosing data available",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F13732629\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?20/22/20839?source=see_link\">",
"      see \"Enalaprilat (intravenous): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use lower listed initial dose in patients with hyponatremia, hypovolemia, severe CHF, decreased renal function, or in those receiving diuretics",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants and Children:",
"     <b>",
"      Hypertension:",
"     </b>",
"     I.V.: 5-10",
"     <b>",
"      mcg",
"     </b>",
"     /kg/dose every 8-24 hours; maximum dose:1.25 mg/dose; frequency determined by clinical response (eg, blood pressure readings); monitor patients carefully; some patients may require higher doses (NHBPEP, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adolescents and Adults:",
"     <b>",
"      Hypertension:",
"     </b>",
"     I.V.: 0.625-1.25 mg/dose every 6 hours; doses as high as 5 mg/dose every 6 hours have been tolerated for up to 36 hours; little experience with doses &gt;20 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Aronoff, 2007:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     GFR &gt;50 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : No dosage adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     GFR 10-50 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer 75% of usual dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     GFR &lt;10 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer 50% of usual dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Alternate recommendations: Others suggest avoiding use in infants, children, and adolescents &le;16 years of age with GFR &lt;30 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Manufacturer&rsquo;s labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;30 mL/minute: No dosage adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;30 mL/minute: Initiate with 0.625 mg; if after 1 hour clinical response is unsatisfactory, may repeat. May then administer 1.25 mg every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Alternate recommendations (Aronoff, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     GFR &gt;50 mL/minute: No dosage adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     GFR 10-50 mL/minute: Administer 50% to 100% of usual dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     GFR &lt;10 mL/minute: Administer 25% to 50% of usual dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Peritoneal dialysis: Supplemental dose is not necessary, although some removal of drug occurs.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F13657027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 1.25 mg/mL (1 mL, 2 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F13655455\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F13732630\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer as I.V. infusion (undiluted or further diluted) over 5 minutes; to deliver small I.V. doses, a dilution with NS to a final concentration of  25 mcg/mL can be used",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F13655528\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in dextran 40 10% in dextrose 5%, D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, hetastarch 6% in NS, Normosol&reg;-R, NS, Plasma-Lyte&reg; A.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Allopurinol, amifostine, amikacin, aminophylline,  ampicillin, ampicillin/sulbactam, aztreonam, bivalirudin, butorphanol, calcium gluconate, cefazolin, ceftazidime, chloramphenicol, cimetidine, cisatracurium, cladribine, clindamycin, dexmedetomidine, dobutamine, docetaxel, dopamine, doripenem, doxorubicin liposome, erythromycin lactobionate, esmolol, etoposide phosphate, famotidine, fenoldopam, fentanyl, filgrastim, ganciclovir, gemcitabine, gentamicin, granisetron, heparin, hetastarch in lactate electrolyte injection (Hextend&reg;), hydrocortisone sodium succinate, labetalol, lidocaine, linezolid, magnesium sulfate, melphalan, meropenem, methylprednisolone sodium succinate, metronidazole, morphine, nafcillin, nicardipine, nitroprusside, oxaliplatin, pemetrexed, penicillin G potassium, phenobarbital, piperacillin, piperacillin/tazobactam, potassium chloride, potassium phosphates, propofol, ranitidine, remifentanil, sodium acetate, sulfamethoxazole/trimethoprim, teniposide, thiotepa, tobramycin, vancomycin, vinorelbine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B cholesteryl sulfate complex, cefepime, nesiritide, pantoprazole, phenytoin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Compatibility in syringe: Incompatible: Pantoprazole.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F13732626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store intact vials below 30&deg;C (86&deg;F); solutions for I.V. infusion mixed in NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, or D",
"     <sub>",
"      5",
"     </sub>",
"     LR are stable for 24 hours at room temperature",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F13732621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypertension when oral therapy is not practical (FDA approved in adults); has also been used for heart failure",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F13655452\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Significant differences exist between oral and I.V. dosing. Use caution when converting from one route of administration to another.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F13655521\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Since enalapril is converted to enalaprilat, adverse reactions associated with enalapril may also occur with enalaprilat (also refer to Enalapril monograph).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: Hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rare but important or life-threatening: Angioedema, constipation, cough, dizziness, fatigue, fever, MI, rash",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F13732622\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to enalapril, enalaprilat, any component, or other ACE inhibitors; patients with idiopathic or hereditary angioedema or a history of angioedema with ACE inhibitors",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F13732719\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with renal impairment; dosage reduction may be necessary; avoid rapid dosage escalation which may lead to further renal impairment. Use with caution in patients with unstented unilateral/bilateral renal artery stenosis. When unstented bilateral renal artery stenosis is present, use is generally avoided due to the elevated risk of deterioration in renal function unless possible benefits outweigh risks.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use with caution when initiating therapy and in volume-depleted patients; may cause symptomatic hypotension with or without syncope, usually with the first several doses; correct volume depletion prior to initiation; initiate lower doses in patients with sodium or volume depletion; close monitoring of patient is required especially with initial dosing and dosing increases; blood pressure must be lowered at a rate appropriate for the patient's clinical condition. Although dose reduction may be necessary, hypotension alone is not a reason for discontinuation of future ACE inhibitor use especially in patients with heart failure where a reduction in systolic blood pressure is a desirable observation. Use caution in patients with ischemic heart disease or cerebrovascular disease during therapy initiation; observe closely due to the potential consequences posed by falling blood pressure (eg, MI, stroke); fluid replacement may be required to restore blood pressure; therapy may then be resumed; discontinue therapy in patients whose hypotension recurs. Use with caution in patients with severe aortic stenosis; may reduce coronary perfusion resulting in ischemia. Use with caution in patients with hypertrophic cardiomyopathy (HCM) and outflow tract obstruction since reduction in afterload may worsen symptoms associated with this condition.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     May cause hyperkalemia; risk factors include renal dysfunction, diabetes mellitus, concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salts; use with caution, if at all, with these agents, and monitor potassium closely.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use with caution before, during, or immediately after major surgery; cardiopulmonary bypass, intraoperative blood loss, or vasodilating anesthesia increases endogenous renin release; use of ACE inhibitors perioperatively will blunt angiotensin II formation and may result in hypotension.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     An ACE inhibitor cough is a dry, hacking, nonproductive one that usually occurs within the first few months of treatment and should generally resolve within 1-4 weeks after discontinuation of the ACE inhibitor. In pediatric patients, an isolated dry hacking cough lasting &gt;3 weeks was reported in seven of 42 pediatric patients (17%) receiving ACE inhibitors (von Vigier, 2000); a review of pediatric randomized-controlled ACE inhibitor trials reported a lower incidence of  3.2% (Baker-Smith, 2010). Other causes of cough should be considered (eg, pulmonary congestion in patients with heart failure) and excluded prior to discontinuation.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F13732623\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Angioedema can occur at any time during treatment (especially following first dose). The relative risk of angioedema with ACE inhibitors is higher within the first 30 days of use (compared to &gt;1 year of use), for Black Americans (compared to Whites), for lisinopril or enalapril (compared to captopril), and for patients previously hospitalized within 30 days (Brown, 1996). Angioedema may occur in the head, neck, extremities, or intestines; patients with angioedema of the intestines may present with abdominal pain (with or without nausea or vomiting); angioedema of the larynx, glottis, or tongue may cause airway obstruction, especially in patients with a history of airway surgery. Prolonged monitoring may be required, even in patients with swelling of only the tongue (ie, without respiratory distress) because treatment with corticosteroids and antihistamines may not be sufficient; very rare fatalities have occurred with angioedema of the larynx or tongue; appropriate treatment (eg, establishing patent airway and/or SubQ epinephrine) should be readily available for patients with angioedema of larynx, glottis, or tongue, in whom airway obstruction is likely to occur.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Anaphylactic/anaphylactoid reactions can occur with ACE inhibitors. Life-threatening anaphylactoid reactions may be seen during hemodialysis (eg, CVVHD) with high-flux dialysis membranes (eg, AN69), and rarely, during low density lipoprotein apheresis with dextran sulfate cellulose. Rare cases of anaphylactoid reactions have been reported in patients undergoing sensitization treatment with hymenoptera (bee, wasp) venom while receiving ACE inhibitors.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Enalapril has been associated with rare but potentially fatal cases of agranulocytosis, neutropenia, or leukopenia with myeloid hypoplasia; higher risk for development of neutropenia is associated with renal impairment; risk is further increased in patients with both renal impairment and collagen vascular disease (eg, systemic lupus erythematosus). Onset of neutropenia is usually within 3 months of enalapril initiation; closely monitor CBC with differential for the first 3 months of therapy and periodically thereafter in these patients; neutrophil count generally returns to baseline within 2 weeks of discontinuation.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     ACE inhibitor use has been associated with deterioration of renal function and/or increases in serum creatinine, particularly in patients with low renal blood flow (eg, renal artery stenosis, heart failure) whose glomerular filtration rate (GFR) is dependent on efferent arteriolar vasoconstriction by angiotensin II; deterioration may result in oliguria, acute renal failure, and progressive azotemia. Small increases in serum creatinine may occur following initiation; consider discontinuation only in patients with progressive and/or significant deterioration in renal function.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A rare toxicity associated with ACE inhibitors includes cholestatic jaundice, which may progress to fulminant hepatic necrosis; discontinue if marked elevation of hepatic transaminases or jaundice occurs and initiate appropriate medical treatment.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Concomitant use of an ARB or renin inhibitor (eg, aliskiren) is associated with an increased risk of hypotension, hyperkalemia, and renal dysfunction. Concomitant use with aliskiren should be avoided in patients with GFR &lt;60 mL/minute and is contraindicated in patients with diabetes mellitus (regardless of GFR).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Injectable product contains benzyl alcohol (9 mg/mL) which may cause allergic reactions in susceptible individuals; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse; use enalaprilat products containing benzyl alcohol with caution in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate, a metabolite of benzyl alcohol, displaces bilirubin from protein binding sites.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13382876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F13382875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: May enhance the hyperkalemic effect of ACE Inhibitors. Aliskiren may enhance the hypotensive effect of ACE Inhibitors. Aliskiren may enhance the nephrotoxic effect of ACE Inhibitors. Management: Avoid aliskiren use with ACEIs or ARBs in patients with diabetes or estimated glomerular filtration rate below 60 mL/min. In other patients receiving these combinations, monitor serum potassium, serum creatinine, and blood pressure periodically.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: ACE Inhibitors may enhance the potential for allergic or hypersensitivity reactions to Allopurinol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprotinin: May diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AzaTHIOprine: ACE Inhibitors may enhance the myelosuppressive effect of AzaTHIOprine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: May enhance the hyperkalemic effect of ACE Inhibitors. Canagliflozin may enhance the hypotensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): ACE Inhibitors may enhance the nephrotoxic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DPP-IV Inhibitors: May enhance the adverse/toxic effect of ACE Inhibitors. Specifically, the risk of angioedema may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: May enhance the adverse/toxic effect of ACE Inhibitors. Specifically, the risk of angioedema may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ferric Gluconate: ACE Inhibitors may enhance the adverse/toxic effect of Ferric Gluconate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gold Sodium Thiomalate: ACE Inhibitors may enhance the adverse/toxic effect of Gold Sodium Thiomalate. An increased risk of nitritoid reactions has been appreciated.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Icatibant: May diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Dextran Complex: ACE Inhibitors may enhance the adverse/toxic effect of Iron Dextran Complex. Specifically, patients receiving an ACE inhibitor may be at an increased risk for anaphylactic-type reactions.  Management: Follow iron dextran recommendations closely regarding both having resuscitation equipment and trained personnel on-hand prior to iron dextran administration and the use of a test dose prior to the first therapeutic dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: ACE Inhibitors may increase the serum concentration of Lithium.  Management: Lithium dosage reductions will likely be needed following the addition of an ACE inhibitor.  Monitor patient response to lithium closely following addition or discontinuation of concurrent ACE inhibitor treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Loop Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: ACE Inhibitors may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Salts: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May diminish the antihypertensive effect of ACE Inhibitors. They may also diminish other beneficial pharmacodynamic effects desired for the treatment of CHF.  The effects are likely dose-related.  100 mg doses aspirin appear to cause no problems, whereas 300 mg doses appear to significantly affect ACE Inhibitor efficacy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: ACE Inhibitors may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with ACEIs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Thiazide Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TiZANidine: May enhance the hypotensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F13732625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Limit salt substitutes or potassium-rich diet. Avoid natural licorice (causes sodium and water retention and increases potassium loss).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F13655461\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (1st trimester); D (2nd and 3rd trimesters) (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13655462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"     Enalaprilat, the active metabolite of enalapril, crosses the placenta; teratogenic effects may occur following maternal use during pregnancy. Drugs that act on the renin-angiotensin system are associated with oligohydramnios. Oligohydramnios, due to decreased fetal renal function, may lead to fetal lung hypoplasia and skeletal malformations. The use of these drugs in pregnancy is also associated with anuria, hypotension, renal failure, skull hypoplasia, and death in the fetus/neonate. Chronic maternal hypertension itself is also associated with adverse events in the fetus/infant. ACE inhibitors are not recommended during pregnancy to treat maternal hypertension or heart failure. Use of an ACE inhibitor should also be avoided in any woman of reproductive age. Women who are planning a pregnancy should be considered for other medication options if an ACE inhibitor is currently prescribed or the ACE inhibitor should be discontinued as soon as possible once pregnancy is detected. The exposed fetus should be monitored for fetal growth, amniotic fluid volume, and organ formation. Infants exposed to an ACE inhibitor",
"     <i>",
"      in utero",
"     </i>",
"     should be monitored for hyperkalemia, hypotension, and oliguria.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13732631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, renal function, WBC, serum potassium, serum glucose; monitor for angioedema and anaphylactoid reactions",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F13732627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Competitive inhibitor of angiotensin-converting enzyme (ACE); prevents conversion of angiotensin I to angiotensin II, a potent vasoconstrictor; results in lower levels of angiotensin II which causes an increase in plasma renin activity and a reduction in aldosterone secretion; a CNS mechanism may also be involved in hypotensive effect as angiotensin II increases adrenergic outflow from CNS; vasoactive kallikreins may be decreased in conversion to active hormones by ACE inhibitors, thus reducing blood pressure",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F13733143\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Antihypertensive effect:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: Within 15 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maximum effect: Within 1-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: Dose dependent, usually 4-6 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F13732628\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 50% to 60%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     CHF: Neonates (n=3; PNA: 10-19 days): 11.9 hours (range: 5.9-15.6 hours) (Nakamura, 1994)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     CHF: Infants  and Children &le;6.5 years of age (n=11): 11.1 hours (range: 5.1-20.8 hours) (Nakamura, 1994)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants 6 weeks to 8 months: 6-10 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: 35-38 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: Principally in urine (60% to 80%) with some fecal excretion",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F13732632\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?17/24/17796?source=see_link\">",
"      see \"Enalaprilat (intravenous): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Limit alcohol. Notify physician immediately if swelling of face, lips, tongue, or difficulty in breathing occurs; if these occur, do not take any more doses until a physician can be consulted. Notify physician if vomiting, diarrhea, excessive perspiration, dehydration, or persistent cough occurs. Do not use a salt substitute (potassium-containing) without physician advice. May cause dizziness, fainting, and lightheadedness, especially in first week of therapy; sit and stand up slowly. May cause rash. Report sore throat, fever, other signs of infection, or other side effects. This medication may cause injury and death to the developing fetus when used during pregnancy; women of childbearing potential should be informed of potential risk; consult prescriber for appropriate contraceptive measures; this medication should be discontinued as soon as possible once pregnancy is detected.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Baker-Smith CM, Benjamin DK Jr, Califf RM, et al, \"Cough in Pediatric Patients Receiving Angiotensin-Converting Enzyme Inhibitor Therapy or Angiotensin Receptor Blocker Therapy in Randomized Controlled Trials,\"",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 2010, 87(6):668-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/20/19783/abstract-text/20130570/pubmed\" id=\"20130570\" target=\"_blank\">",
"        20130570",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brown NJ, Ray WA, Snowden M, et al, \"Black Americans Have an Increased Rate of Angiotensin Converting Enzyme Inhibitor-Associated Angioedema,\"",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1996, 60(1):8-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/20/19783/abstract-text/8689816/pubmed\" id=\"8689816\" target=\"_blank\">",
"        8689816",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/20/19783/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Marcadis ML, Kraus DM, Hatzopoulos FK, et al, \"Use of Enalaprilat for Neonatal Hypertension,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1991, 119(3):505-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/20/19783/abstract-text/1652634/pubmed\" id=\"1652634\" target=\"_blank\">",
"        1652634",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nakamura H, Ishii M, Sugimura T, et al, &ldquo;The Kinetic Profiles of Enalapril and Enalaprilat and Their Possible Developmental Changes in Pediatric Patients With Congestive Heart Failure,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1994, 56(2):160-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/20/19783/abstract-text/8062492/pubmed\" id=\"8062492\" target=\"_blank\">",
"        8062492",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents, \"The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2004, 114(2 Suppl):555-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/20/19783/abstract-text/15286277/pubmed\" id=\"15286277\" target=\"_blank\">",
"        15286277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      von Vigier RO, Mozzettini S, Truttmann AC, et al, &ldquo;Cough is Common in Children Prescribed Converting Enzyme Inhibitors,&rdquo;",
"      <i>",
"       Nephron",
"      </i>",
"      , 2000, 84(1):98.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/20/19783/abstract-text/10644922/pubmed\" id=\"10644922\" target=\"_blank\">",
"        10644922",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wells TG, Bunchman TE, and Kearns GL, \"Treatment of Neonatal Hypertension With Enalaprilat,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1990, 117(4):664-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/20/19783/abstract-text/2170612/pubmed\" id=\"2170612\" target=\"_blank\">",
"        2170612",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83324 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-219.243.220.100-9E6818F356-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_20_19783=[""].join("\n");
var outline_f19_20_19783=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13657030\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13655454\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13732620\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13732720\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13732629\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13657027\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13655455\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13732630\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13655528\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13732626\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13732621\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13655452\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13655521\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13732622\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13732719\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13732623\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13382876\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13382875\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13732625\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13655461\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13655462\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13732631\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13732627\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13733143\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13732628\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13732632\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/83324\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/83324|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?20/22/20839?source=related_link\">",
"      Enalaprilat (intravenous): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?17/24/17796?source=related_link\">",
"      Enalaprilat (intravenous): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_20_19784="Advanced case 1 with answer";
var content_f19_20_19784=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F69976&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F69976&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Electrocardiogram in hypothermia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 285px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The ECG reveals marked sinus bradycardia (about 40 beats/min) with a prolonged PR interval (PR interval = 0.23 sec). The slow heart rate in this patient is due to hypothermia (90&deg;F, 32.2&deg;C), which also produces prominent convex deflections at the J point (junction of QRS and ST segments) that are best seen in the precordial leads. The J waves or Osborn waves (arrows) are characteristic of severe hypothermia and resolve with rewarming; how they occur is not fully understood (Wang D, Yan GX, Antzelevitch C. The J Wave syndromes and their role in sudden cardiac death. Card Electrophysiol Clin 2011; 3:47).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ary Goldberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_20_19784=[""].join("\n");
var outline_f19_20_19784=null;
var title_f19_20_19785="Linear scleroderma face";
var content_f19_20_19785=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F83578%7EDERM%2F83579&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F83578%7EDERM%2F83579&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Linear scleroderma (morphea): Early manifestation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Linear scleroderma (morphea) of the face: Advanced lesion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_20_19785=[""].join("\n");
var outline_f19_20_19785=null;
var title_f19_20_19786="Cutaneous manifestations of sarcoidosis";
var content_f19_20_19786=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cutaneous manifestations of sarcoidosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/20/19786/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/20/19786/contributors\">",
"     Steven Prystowsky, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/20/19786/contributors\">",
"     Miguel Sanchez, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/20/19786/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/20/19786/contributors\">",
"     Jeffrey Callen, MD, FACP, FAAD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/20/19786/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/20/19786/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/20/19786/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 26, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H18191748\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sarcoidosis is a granulomatous disease characterized by the presence of noncaseating granulomas in organs and tissue, such as the skin, lung, lymph nodes, eyes, joints, brain, kidneys, and heart. Cutaneous lesions may present with a variety of morphologies, including papules, nodules, plaques, and infiltrated scars.",
"   </p>",
"   <p>",
"    The diagnosis of cutaneous sarcoidosis is supported by the recognition of compatible clinical features, the detection of classic histopathologic findings, and the exclusion of other granulomatous disorders. Compared with other sites of sarcoidal involvement, histopathologic sampling of lesions in the skin is a relatively simple and safe procedure. When present, cutaneous lesions can be a valuable asset in the confirmation of a diagnosis of sarcoidosis.",
"   </p>",
"   <p>",
"    In addition to skin lesions that display noncaseating granulomas on biopsy, cutaneous eruptions that are not specific for sarcoidosis also may occur in patients with sarcoidosis. Erythema nodosum is the most frequent nonspecific cutaneous disorder associated with sarcoidosis.",
"   </p>",
"   <p>",
"    The clinical manifestations and diagnosis of cutaneous sarcoidosis will be discussed here. The management of cutaneous sarcoidosis, the pathogenesis of sarcoidosis, and the clinical features, diagnosis, and treatment of extracutaneous sarcoidosis are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/8/16522?source=see_link\">",
"     \"Management of cutaneous sarcoidosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6376?source=see_link\">",
"     \"Pathogenesis of sarcoidosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=see_link\">",
"     \"Clinical manifestations and diagnosis of sarcoidosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/43/11961?source=see_link\">",
"     \"Treatment of pulmonary sarcoidosis with glucocorticoids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38074?source=see_link\">",
"     \"Treatment of pulmonary sarcoidosis with alternatives to glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5344750\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin manifestations of sarcoidosis are estimated to occur in approximately 25 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/1-6\">",
"     1-6",
"    </a>",
"    ] and are divided into specific and nonspecific lesions based upon histopathologic features [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/7\">",
"     7",
"    </a>",
"    ]. Specific skin lesions contain noncaseating (sarcoidal) granulomas, which represent the classic histopathologic findings in lesional tissue. All other cutaneous findings associated with sarcoidosis are classified as nonspecific. Patients may have both specific and nonspecific skin findings [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Specific lesions are estimated to occur in 9 to 15 percent of patients with sarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Although their histopathologic features are similar, the clinical manifestations of specific lesions vary widely. Papules, nodules, plaques, and infiltrated scars are among the most common presentations; other manifestations also occur [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H18191778\">",
"     'Clinical manifestations'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The nonspecific lesions of sarcoidosis include a wide spectrum of disorders. Erythema nodosum, which typically presents as inflammatory, tender nodules on the lower legs, is the most common nonspecific cutaneous lesion of sarcoidosis. In one study of 516 patients with sarcoidosis, erythema nodosum was present in 20 percent of all patients and in 62 percent of patients with cutaneous disease [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/11\">",
"     11",
"    </a>",
"    ]. Other examples of nonspecific cutaneous manifestations include calcinosis cutis, Sweet syndrome, and nail clubbing [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/7,13\">",
"     7,13",
"    </a>",
"    ]. Although some authors have considered erythema multiforme a nonspecific manifestation of sarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/14\">",
"     14",
"    </a>",
"    ], there is little evidence to support a definitive link between sarcoidosis and erythema multiforme. (See",
"    <a class=\"local\" href=\"#H18191920\">",
"     'Nonspecific eruptions'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18191762\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The factors that lead to the development of sarcoidosis are not well understood. The pathogenesis is thought to involve genetically influenced dysregulation of the Th1 immune response to one or more extrinsic antigens, an event that could lead to the over-activation of inflammatory pathways and subsequent granuloma formation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"   </p>",
"   <p>",
"    Multiple foreign bodies, infectious agents, and medications have been proposed as potential contributors to the development of sarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/15,17-20\">",
"     15,17-20",
"    </a>",
"    ]. It is unknown whether environmental factors that come in contact with the skin serve as a nidus for granuloma formation or stimulate an aberrant immune response through other mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/15,16,21\">",
"     15,16,21",
"    </a>",
"    ]. Additional studies are necessary to explore the pathogenesis of cutaneous sarcoidosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6376?source=see_link\">",
"     \"Pathogenesis of sarcoidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H245206\">",
"    <span class=\"h1\">",
"     HISTOPATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The characteristic histopathologic finding in specific lesions of cutaneous sarcoidosis is the presence of sarcoidal noncaseating granulomas, which consist of aggregates of epithelioid histiocytes, giant cells, and mature macrophages (",
"    <a class=\"graphic graphic_picture graphicRef80383 graphicRef54204 \" href=\"UTD.htm?36/36/37450\">",
"     picture 1A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/22\">",
"     22",
"    </a>",
"    ]. These granulomas are surrounded by sparse lymphocytic infiltrates composed primarily of CD4+ T-cell lymphocytes and a few CD8+ lymphocytes. The absence of a dense lymphocytic infiltrate, such as is common in cutaneous lesions of tuberculosis, has led to the use of the term &ldquo;naked granulomas&rdquo; to describe this classic histopathologic finding in sarcoidosis.",
"   </p>",
"   <p>",
"    The giant cells located within sarcoidal granulomas may contain intracytoplasmic inclusions. These structures are found in other granulomas and are not pathognomonic of sarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Asteroid bodies",
"      </strong>",
"      &ndash; stellate eosinophilic inclusions made up of complex lipids",
"     </li>",
"     <li>",
"      <strong>",
"       Schaumann (conchoidal) bodies",
"      </strong>",
"      &ndash; round or oval inclusions consisting of laminated calcium oxalate; these may represent residual bodies of lysosomes",
"     </li>",
"     <li>",
"      <strong>",
"       Crystalline inclusions",
"      </strong>",
"      &ndash; Colorless, round or oval, refractile, nonlaminated inclusion bodies composed of calcium oxalate that may represent precursors of Schaumann bodies",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The histopathologic diagnosis of sarcoidosis is complicated by the fact that not all lesions of sarcoidosis demonstrate classic histopathologic findings [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/5,20,22-28\">",
"     5,20,22-28",
"    </a>",
"    ]. While naked granulomas have been strongly associated with sarcoidosis, they are not always present. It is estimated that 71 to 89 percent of specific lesions of sarcoidosis contain typical sarcoidal granulomas [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/5,20,29\">",
"     5,20,29",
"    </a>",
"    ]. Occasional cases of sarcoidosis may exhibit florid lymphocytic infiltrates at the periphery of granulomas, central caseation, vasculitis, or increased dermal mucin [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/5,20,22-28\">",
"     5,20,22-28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Epidermal changes are present in some histopathologic specimens of sarcoidosis and are dependent upon lesion type. Atrophy and parakeratotic scale are the most common epidermal changes detected. Epidermal spongiosis, hyperplasia, and ulceration are present occasionally.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5641743\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The histopathologic differential diagnosis of specific lesions of cutaneous sarcoidosis includes a variety of other granulomatous disorders. Examples include [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/30\">",
"     30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Foreign body reactions &ndash;",
"      </strong>",
"      The identification of refractile material with polariscopic examination of a histopathologic specimen suggests a foreign body reaction. Giant cells with multiple nuclei in a haphazard arrangement (foreign-body giant cells) are often present.",
"     </li>",
"     <li>",
"      <strong>",
"       Tuberculosis (lupus vulgaris variant) &ndash;",
"      </strong>",
"      The histopathologic features of lupus vulgaris can closely resemble sarcoidosis. A granulomatous infiltrate located primarily in the upper dermis, a more prominent peripheral lymphocytic inflammatory infiltrate, and the presence of significant central necrosis in granulomas suggest a diagnosis of lupus vulgaris. Lesions of lupus vulgaris also may demonstrate ulceration, acanthosis, and pseudoepitheliomatous hyperplasia. A negative acid-fast stain does not rule out lupus vulgaris.",
"     </li>",
"     <li>",
"      <strong>",
"       Tuberculoid leprosy &ndash;",
"      </strong>",
"      Granulomas in tuberculoid leprosy are often elongated and located along the course of nerves. Unlike in sarcoidosis, central caseation is a common feature of granulomas in tuberculoid leprosy. Acid fast stains reveal the presence of acid-fast bacilli in a minority of cases of tuberculoid leprosy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Deep fungal and atypical mycobacterial infections should also be considered in the histopathologic differential diagnosis of sarcoidosis. Microbial stains and fresh tissue cultures can assist with ruling out these diagnoses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H245665\">",
"    <span class=\"h1\">",
"     ASSOCIATION WITH SYSTEMIC DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk for the development of systemic involvement in patients who present with disease limited to the skin is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. In one series that included eight patients who presented with only specific lesions of cutaneous sarcoidosis, all eight developed systemic disease within three years [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with the lupus pernio variant of cutaneous sarcoidosis or sarcoidosis manifesting in scars appear to have a high risk for pulmonary disease. In a retrospective study of 516 patients with sarcoidosis, pulmonary parenchymal involvement was present more frequently in patients with lupus pernio or sarcoidosis involving scar tissue (64 and 40 percent, respectively) than in patients with erythema nodosum or other specific lesions of sarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H18191808\">",
"     'Lupus pernio'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18191778\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific eruptions of sarcoidosis are characterized by the presence of sarcoidal granulomas on histopathologic examination. Specific lesions may occur in a variety of morphologies, but most commonly appear as papules or nodules. Lesions are often asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18191794\">",
"    <span class=\"h2\">",
"     Papular sarcoidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Papular sarcoidosis is",
"    <strong>",
"    </strong>",
"    a common specific cutaneous manifestation of sarcoidosis (",
"    <a class=\"graphic graphic_picture graphicRef78691 graphicRef69405 \" href=\"UTD.htm?11/14/11497\">",
"     picture 2A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/14\">",
"     14",
"    </a>",
"    ]. This variant presents with numerous nonscaly, 1 to 10 mm papules. Lesions can be skin-colored, yellow-brown, red-brown, violaceous, or hypopigmented. In some cases, the papules demonstrate a slight central depression [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Papular sarcoidosis most frequently occurs on the face, with a predilection for the eyelids and nasolabial folds [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/14\">",
"     14",
"    </a>",
"    ]. Coalescence of lesions may lead to the formation of annular or nonannular plaques [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/34\">",
"     34",
"    </a>",
"    ]. Upon resolution, faintly discolored, occasionally atrophic macules may remain at previous sites of involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Papular lesions of sarcoidosis may clinically resemble granulomatous rosacea, appendageal tumors, xanthelasma, or xanthomas [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/7\">",
"     7",
"    </a>",
"    ]. Infrequently, lesions may resemble lichen nitidus or erythema multiforme (",
"    <a class=\"graphic graphic_picture graphicRef73271 \" href=\"UTD.htm?18/62/19426\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6092903\">",
"    <span class=\"h2\">",
"     Nodular sarcoidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nodular sarcoidosis is a relatively common form of cutaneous sarcoidosis that results from large collections of sarcoidal granulomas in the dermis or subcutaneous tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. In one series of patients with skin manifestations of sarcoidosis, nodules were present in 10 out of 28 patients (36 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/12\">",
"     12",
"    </a>",
"    ]. Nodules tend to be between 1 and 2 cm in diameter and may be single or multiple. On the nose, nodular sarcoidosis can resemble rhinophyma (",
"    <a class=\"graphic graphic_picture graphicRef50697 \" href=\"UTD.htm?22/5/22612\">",
"     picture 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29997403\">",
"    <span class=\"h3\">",
"     Subcutaneous sarcoidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The terms subcutaneous sarcoidosis and Darier-Roussy sarcoidosis are used to describe nodular sarcoidosis that primarily involves the subcutaneous tissue (",
"    <a class=\"graphic graphic_picture graphicRef78202 \" href=\"UTD.htm?21/45/22225\">",
"     picture 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/5\">",
"     5",
"    </a>",
"    ]. Subcutaneous sarcoidosis presents as erythematous, flesh-colored, violaceous, or hyperpigmented nodules that are most commonly located on the upper extremities [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/40\">",
"     40",
"    </a>",
"    ]. On the forearms, lesions often coalesce to form linear bands. The nodules may be asymptomatic or mildly tender [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Estimates of the frequency of subcutaneous lesions in patients with sarcoidosis vary, ranging from 1 to 12 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/5,41-43\">",
"     5,41-43",
"    </a>",
"    ]. Based upon data from one retrospective review of 54 patients with subcutaneous sarcoidosis, the disorder may be more common in females and in middle-aged adults and may be associated with a predisposition to autoimmune disease [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/40\">",
"     40",
"    </a>",
"    ]. Although some reports have suggested that subcutaneous sarcoidosis is a marker for an increased risk for systemic disease, the relationship remains controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/5,40,42,44\">",
"     5,40,42,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with sarcoidosis have an increased risk for the development of erythema nodosum, which also can present with erythematous, tender nodules. The possibility of erythema nodosum should be considered in patients with sarcoidosis who present with nodular lesions, particularly when the nodules are located on the lower legs. Biopsy is useful for distinguishing between these diagnoses [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H18191929\">",
"     'Erythema nodosum'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Other lesions that may resemble subcutaneous sarcoidosis on clinical examination include lipomas, cysts, subcutaneous granuloma annulare, foreign body granulomas, or cutaneous manifestations of lymphoproliferative malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2494193\">",
"    <span class=\"h2\">",
"     Maculopapular sarcoidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of maculopapular sarcoidosis is difficult to assess due to the fact that some reports in the literature include the papular variant of sarcoidosis in this category [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/5,11\">",
"     5,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Characteristically, lesions are asymptomatic or pruritic, and consist of slightly infiltrated, slightly hyperpigmented patches studded with slightly raised papules that are often around 1 mm in diameter (",
"    <a class=\"graphic graphic_picture graphicRef66626 \" href=\"UTD.htm?13/5/13396\">",
"     picture 6",
"    </a>",
"    ). Lesions are usually red, brown, or violaceous. Facial skin, especially the periorificial or eyelid area, is the most common site of involvement. Lesions may also occur on the neck, trunk, extremities, or mucous membranes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18191801\">",
"    <span class=\"h2\">",
"     Plaque sarcoidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plaque sarcoidosis often presents with oval or annular, indurated, discrete plaques that are flesh-colored, erythematous, or brown (",
"    <a class=\"graphic graphic_picture graphicRef52189 graphicRef59868 \" href=\"UTD.htm?37/12/38087\">",
"     picture 7A-B",
"    </a>",
"    ). Occasionally, scale is present. Frequent sites of involvement include the shoulders and arms, back, and buttocks [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of other cutaneous disorders share clinical features with plaque sarcoidosis and should be considered in the differential diagnosis. Examples of disorders that may resemble plaque sarcoidosis include psoriasis, lichen planus, discoid lupus, granuloma annulare, cutaneous T cell lymphoma, Kaposi&rsquo;s sarcoma, and secondary syphilis. [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H18191829\">",
"     'Psoriasiform sarcoidosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Less common variants of plaque sarcoidosis are reviewed below. (See",
"    <a class=\"local\" href=\"#H18191822\">",
"     'Angiolupoid sarcoidosis'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H18191829\">",
"     'Psoriasiform sarcoidosis'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H18191850\">",
"     'Verrucous sarcoidosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18191808\">",
"    <span class=\"h2\">",
"     Lupus pernio",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lupus pernio is characterized by violaceous or erythematous indurated papules, plaques, or nodules that are primarily distributed on the central face (",
"    <a class=\"graphic graphic_picture graphicRef76184 graphicRef63312 \" href=\"UTD.htm?31/59/32696\">",
"     picture 8A-B",
"    </a>",
"    ), usually the alar rim, nasal tip, and cheeks. Other frequent sites of involvement include the ears and lips. Less commonly, lesions may affect the dorsal hands, fingers, or toes. Without treatment, the lesions progressively increase in thickness, size, and induration, eventually resulting in considerable cosmetic disfigurement. Scarring may be present after lesion resolution [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of lupus pernio appears to be associated with an increased risk for extracutaneous disease, particularly sarcoidosis involving the respiratory tract [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/1,5,46-48\">",
"     1,5,46-48",
"    </a>",
"    ]. Among 35 patients with lupus pernio in one case series, intrathoracic disease (lymphadenopathy or pulmonary abnormalities), upper respiratory disease, reticuloendothelial involvement, and ocular lesions were present in 74, 54, 54, and 37 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/49\">",
"     49",
"    </a>",
"    ]. When severe, granulomatous inflammation of the upper respiratory tract can result in airway obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lytic and cystic bone lesions, especially in the hands and feet, can be present in bone underlying lesions of lupus pernio [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/46\">",
"     46",
"    </a>",
"    ]. Among the 35 patients with lupus pernio in the case series described above, bone cysts were found in 50 percent of the patients who were radiographed, and in half of these cases, cysts were present in both the hands and feet [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H797125\">",
"    <span class=\"h2\">",
"     Hypopigmented sarcoidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypopigmented sarcoidosis affects almost exclusively dark-skinned persons of African descent. Lesions manifest as hypopigmented, well-demarcated, round to oval patches or barely raised plaques (",
"    <a class=\"graphic graphic_picture graphicRef74163 graphicRef63313 \" href=\"UTD.htm?12/39/12921\">",
"     picture 9A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/14,50\">",
"     14,50",
"    </a>",
"    ]. Skin colored or erythematous papules can be found in the center of some lesions of hypopigmented sarcoidosis, leading to an appearance that resembles a fried egg.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18191815\">",
"    <span class=\"h2\">",
"     Atrophic and ulcerative sarcoidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrophic sarcoidosis is a form of plaque sarcoidosis that presents with depressed rather than elevated plaques. Ulceration may accompany the clinical findings. The term ulcerative-atrophic sarcoidosis may be used to describe lesions that are both atrophic and ulcerated (",
"    <a class=\"graphic graphic_picture graphicRef62363 \" href=\"UTD.htm?10/55/11121\">",
"     picture 10",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ulcerative-atrophic lesions occur in a minority of patients with sarcoidosis. In one retrospective series, ulcerative-atrophic sarcoidosis was detected in 7 out of 147 cases of cutaneous sarcoidosis (5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/52\">",
"     52",
"    </a>",
"    ]. All patients with ulcerative-atrophic lesions presented with other mucocutaneous manifestations of sarcoidosis and the majority also had internal disease. Ulcerative sarcoidosis may be more common in women and black patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/51,52\">",
"     51,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lesions of atrophic sarcoidosis may share features with morphea. In addition, atrophic sarcoidosis can share clinical features with necrobiosis lipoidica or lipodermatosclerosis; these variants often ulcerate. Similar to other specific lesions of sarcoidosis, histopathologic examination of atrophic types of sarcoidosis reveals noncaseating granulomas.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Morpheaform",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      In the morpheaform variant, lesions begin as firm, sclerotic, flesh-colored or hyperpigmented plaques that evolve into depressed lesions over time [",
"      <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/7\">",
"       7",
"      </a>",
"      ]. The lesions occur more frequently on the lower extremities than on the upper extremities [",
"      <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/53\">",
"       53",
"      </a>",
"      ]. Histopathologic examination of the dermis reveals markedly thickened collagen bundles and obliteration of the subcutaneous tissue. Rarely, lesions occur in a linear distribution, a clinical presentation that closely resembles linear morphea [",
"      <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Necrobiosis-lipoidica-like",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      In a rare subtype of atrophic sarcoidosis, the necrobiosis-lipoidica variant, pink to violaceous plaques with depressed centers develop on the shins. Necrobiotic changes in collagen bundles surrounded by epithelioid histiocytes and foreign-body giant cells are present histologically.",
"     </li>",
"     <li>",
"      <strong>",
"       Lipodermatosclerosis-like",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      Lipodermatosclerosis-like atrophic sarcoidosis presents on the lower extremities as brown, indurated, circumferential, progressively fibrotic plaques. This variant of sarcoidosis should be considered in cases of lipodermatosclerosis (sclerosing panniculitis) that do not respond to compression and standard treatments. A feature that favors sarcoidosis is a unilateral distribution [",
"      <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H630708\">",
"    <span class=\"h2\">",
"     Rare variants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angiolymphoid, psoriasiform, and verrucous sarcoidosis are rare variants of plaque sarcoidosis. Ichthyosiform and erythrodermic sarcoidosis are additional uncommon variants that present with extensive cutaneous involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18191822\">",
"    <span class=\"h3\">",
"     Angiolupoid sarcoidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angiolupoid sarcoidosis (also called Brocq-Pautrier angiolupoid) is a variant of plaque sarcoidosis characterized by the presence of prominent large telangiectasias. Usually a single, minimally raised plaque develops on the central face, ears, or scalp; women are most frequently affected (",
"    <a class=\"graphic graphic_picture graphicRef71687 graphicRef70564 \" href=\"UTD.htm?5/18/5416\">",
"     picture 11A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/56\">",
"     56",
"    </a>",
"    ]. The center of the lesion may be relatively lighter in color than the periphery, and in some cases, the plaque may possess an annular configuration. Angiolupoid sarcoidosis may be mistaken for rosacea or a large basal cell carcinoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18191829\">",
"    <span class=\"h3\">",
"     Psoriasiform sarcoidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psoriasiform sarcoidosis is a type of plaque sarcoidosis that presents with well-demarcated, erythematous, scaly plaques that may be indistinguishable from psoriasis (",
"    <a class=\"graphic graphic_picture graphicRef50608 \" href=\"UTD.htm?2/5/2133\">",
"     picture 12",
"    </a>",
"    ). In contrast to psoriatic lesions, sarcoidal plaques may resolve with scarring or atrophy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18191850\">",
"    <span class=\"h3\">",
"     Verrucous sarcoidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lesions of verrucous sarcoidosis consist of well demarcated, exophytic, hyperkeratotic, plaques or discrete, papillomatous, skin-colored papules (",
"    <a class=\"graphic graphic_picture graphicRef62566 \" href=\"UTD.htm?39/9/40085\">",
"     picture 13",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/57\">",
"     57",
"    </a>",
"    ]. Most cases involve the lower extremities. Lesions may resemble warts, prurigo nodularis, or hypertrophic lichen planus [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/57\">",
"     57",
"    </a>",
"    ]. Patients usually have systemic involvement, frequently manifesting as significant pulmonary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18191864\">",
"    <span class=\"h3\">",
"     Ichthyosiform sarcoidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Less than 35 cases of ichthyosiform sarcoidosis have been reported since 1981 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/59\">",
"     59",
"    </a>",
"    ]. The findings consist of adherent, irregular, polygonal, dry, gray or brown scales varying in size from 0.1 to 1 cm. Ichthyosiform sarcoidosis most commonly involves the pretibial area of the lower extremities (",
"    <a class=\"graphic graphic_picture graphicRef53092 \" href=\"UTD.htm?31/3/31807\">",
"     picture 14",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The skin lesions appear concurrently with or precede the diagnosis of systemic sarcoidosis in approximately 75 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/59\">",
"     59",
"    </a>",
"    ]; lesions occur in the setting of established systemic disease in the remainder. It is estimated that 95 percent of patients eventually develop systemic involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The patient&rsquo;s history and the detection of dermal noncaseating granulomas in a biopsy specimen from affected tissue distinguish sarcoidal ichthyosis from other forms of ichthyosis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/61\">",
"     61",
"    </a>",
"    ]. Rarely, sarcoidosis manifests as ichthyosiform erythroderma, with sudden development of diffuse erythema and ichthyotic scale [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/62\">",
"     62",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H18191871\">",
"     'Erythrodermic sarcoidosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18191871\">",
"    <span class=\"h3\">",
"     Erythrodermic sarcoidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erythrodermic sarcoidosis typically begins with slightly infiltrated, erythematous to yellow-brown plaques that subsequently coalesce over large areas of the skin (",
"    <a class=\"graphic graphic_picture graphicRef51460 graphicRef63230 \" href=\"UTD.htm?2/41/2713\">",
"     picture 15A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/63-66\">",
"     63-66",
"    </a>",
"    ]. Desquamation is common. In contrast to classic exfoliative erythroderma, some areas of skin are usually spared. Patients with erythrodermic sarcoidosis may have symptoms or signs of concomitant systemic involvement, such as fever, weight loss, arthralgias, uveitis, and dyspnea [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The absence of large, thick, polygonal scales differentiates erythrodermic sarcoidosis from ichthyosiform erythroderma. The course of the disease is variable. Histopathologic evaluation is necessary to exclude more common causes of erythroderma such as psoriasis, eczema, drug eruptions, and cutaneous T-cell lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/67\">",
"     67",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2494761\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other rare forms of cutaneous sarcoidosis reported in the literature include pustular sarcoidosis and a photodistributed form of sarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/14,68-70\">",
"     14,68-70",
"    </a>",
"    ]. It is unclear whether photodistributed sarcoidosis is a true entity, or whether lesions actually represent the granulomatous variant of rosacea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H244886\">",
"    <span class=\"h1\">",
"     SARCOIDOSIS OF SPECIAL SITES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H797331\">",
"    <span class=\"h2\">",
"     Scar sarcoidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of sarcoidal granulomas in scar tissue is a relatively common manifestation of cutaneous sarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/11\">",
"     11",
"    </a>",
"    ]. In one series of 170 patients with cutaneous sarcoidosis, 15 patients (9 percent) presented with disease involving scars [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/11\">",
"     11",
"    </a>",
"    ]. Scars from surgical incisions, venipuncture, acne, pseudofolliculitis barbae, herpes zoster virus, and other forms of skin trauma are potential sites for the development of lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/71-73\">",
"     71-73",
"    </a>",
"    ]. Affected scars thicken, and occasionally become erythematous or violaceous. Lesions are often asymptomatic, but some patients may note a sensation of irritation.",
"   </p>",
"   <p>",
"    Scar sarcoidosis can occur as early as six months to as long as 59 years after an injury [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/74\">",
"     74",
"    </a>",
"    ]. Scar sarcoidosis can also appear acutely in patients with L&ouml;fgren&rsquo;s syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/12/11463?source=see_link\">",
"     \"Sarcoid arthropathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=see_link&amp;anchor=H23#H23\">",
"     \"Clinical manifestations and diagnosis of sarcoidosis\", section on 'Lofgren's syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Scar sarcoidosis may be more common than recognized since some lesions may be misdiagnosed as hypertrophic scars or keloids. Like sarcoidosis, keloids preferentially affect African-Americans and respond to intralesional corticosteroid therapy.",
"   </p>",
"   <p>",
"    The relationship between scar sarcoidosis and systemic sarcoidosis remains unclear. While some authors have proposed a strong link between scar sarcoidosis and systemic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/75,76\">",
"     75,76",
"    </a>",
"    ], others have commented on a more benign nature and good prognosis in patients who present with isolated scar sarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/7,77\">",
"     7,77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H797338\">",
"    <span class=\"h2\">",
"     Tattoo sarcoidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sarcoidal granulomas can develop in tattoos and may be the initial presentation of sarcoidosis in some patients. Tattoo sarcoidosis can occur within one year of tattoo placement or may develop decades after the tattoo was obtained [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/78\">",
"     78",
"    </a>",
"    ]. Although red ink (cinnabar) tattoos are most commonly affected, sarcoidal infiltration in tattoos created with other pigments can also occur. The development of sarcoidal granulomas in tattoos of the eyebrows and lips has also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Affected tattoos become raised, firm, and edematous (",
"    <a class=\"graphic graphic_picture graphicRef51560 \" href=\"UTD.htm?13/10/13481\">",
"     picture 16",
"    </a>",
"    ). Patients may experience pain or pruritus at sites of involvement.",
"   </p>",
"   <p>",
"    Histopathologic examination reveals the presence of sarcoidal granulomas showing aggregates of epithelioid cells surrounded by peripheral rings of lymphocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/78\">",
"     78",
"    </a>",
"    ]. The histopathologic differential diagnosis includes foreign body reactions to tattoo pigment, which also present with granulomatous infiltrates in the dermis.",
"   </p>",
"   <p>",
"    Since sarcoidal tattoo reactions can be the presenting signs of sarcoidosis, patients who present with these lesions should be evaluated for systemic disease. In one retrospective case series of 19 patients with scar sarcoidosis, hilar adenopathy, uveitis, arthritis, or pulmonary disease were present in 74, 21, 16, and 16 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18191906\">",
"    <span class=\"h2\">",
"     Alopecia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hair loss is an uncommon specific manifestation of sarcoidosis. Sarcoidal alopecia is primarily seen on the scalp; infrequently, hair loss can occur in other areas [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lesions typically present as localized atrophic, annular, or indurated plaques, or flesh-colored or erythematous nodules (",
"    <a class=\"graphic graphic_picture graphicRef57221 \" href=\"UTD.htm?25/25/26005\">",
"     picture 17",
"    </a>",
"    ). Scale is usually absent, but may be seen in some cases. Other cutaneous signs of sarcoidosis, particularly involving the face, are often present [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/79\">",
"     79",
"    </a>",
"    ]. If scalp disease progresses, local destruction and scarring of hair follicles leads to the development of permanent alopecia that is indistinguishable from pseudopelade of Brocq. In some cases, scalp involvement may become extensive, leading to significant hair loss [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Follicular plugging, as seen in discoid lupus erythematosus, may also be present in patients with alopecia secondary to sarcoidosis. [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/80\">",
"     80",
"    </a>",
"    ]. Papular sarcoidosis on the nape of the neck may resemble acne keloidalis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18191913\">",
"    <span class=\"h2\">",
"     Nail sarcoidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sarcoidosis involving the fingers or toes can produce a wide variety of nail plate changes [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/81\">",
"     81",
"    </a>",
"    ], such as thinning, brittleness, pitting, thickening, transverse layering (nail splitting), increased convexity, onycholysis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/82\">",
"     82",
"    </a>",
"    ], subungual hyperkeratosis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/83\">",
"     83",
"    </a>",
"    ], clubbing, pseudoclubbing, paronychia with nail fold fissuring, pterygium [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/84\">",
"     84",
"    </a>",
"    ], longitudinal ridging [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/85\">",
"     85",
"    </a>",
"    ], splinter hemorrhages [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/86\">",
"     86",
"    </a>",
"    ], and red or brown discoloration of the nail bed [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/87,88\">",
"     87,88",
"    </a>",
"    ]. Disease progression can eventually result in pterygium formation (adherence of the proximal nail fold to the nail bed) and total loss of the nail (anonychia).",
"   </p>",
"   <p>",
"    Granulomatous infiltration of the nail matrix and compression by sarcoidal granulomas on nail structures may contribute to the appearance of nail dystrophy. Sarcoidal nail plate dystrophy is often accompanied by phalangeal bone disease.",
"   </p>",
"   <p>",
"    The combination of nail disease and bone involvement can occur in sarcoidal dactylitis, a variant of sarcoidosis that presents with bilateral fusiform or sausage-shaped swellings of the fingers (",
"    <a class=\"graphic graphic_picture graphicRef64864 \" href=\"UTD.htm?18/12/18626\">",
"     picture 18",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/43\">",
"     43",
"    </a>",
"    ]. Radiographic examination of affected digits reveals erosions in the distal phalanges. &ldquo;Drumstick dactylitis,&rdquo; a rare severe form of sarcoidal dactylitis characterized by bulbous swelling of the fingertips, has been associated with lupus pernio [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H244631\">",
"    <span class=\"h2\">",
"     Genital sarcoidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been only a few reports of vulvar sarcoidosis, which can present with papules, plaques, or nodules [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/89-91\">",
"     89-91",
"    </a>",
"    ]. Sarcoidosis of the male genitalia may present as indurated papules, painful nodules with or without ulceration, or swelling of the scrotum or penis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/92-96\">",
"     92-96",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H244638\">",
"    <span class=\"h2\">",
"     Sarcoidosis of the oral cavity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sarcoidosis involving the oral cavity presents as nodules, edema, ulcers, or gingival abnormalities such as gingivitis, gingival hyperplasia, or gingival recession (",
"    <a class=\"graphic graphic_picture graphicRef67531 \" href=\"UTD.htm?3/40/3713\">",
"     picture 19",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/97-100\">",
"     97-100",
"    </a>",
"    ]. In review of 47 cases of sarcoidal involvement of the soft tissues of the oral cavity, nodules and localized swelling were the most frequent manifestations of mucosal disease, occurring in 34 patients (72 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/97\">",
"     97",
"    </a>",
"    ]. In the soft tissues of the oral cavity, the most commonly affected site was the buccal mucosa (28 percent), followed by the gingiva (22 percent), lips (13 percent), floor of the mouth or sublingual glands (11 percent), tongue (11 percent), palate (6 percent), and submandibular gland (4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18191920\">",
"    <span class=\"h1\">",
"     NONSPECIFIC ERUPTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erythema nodosum is the most common nonspecific cutaneous eruption of sarcoidosis. Examples of other nonspecific eruptions include calcinosis cutis, erythema multiforme, prurigo, Sweet syndrome, and nail clubbing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18191929\">",
"    <span class=\"h2\">",
"     Erythema nodosum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erythema nodosum (EN) develops in up to 25 percent of patients with sarcoidosis and is clinically and histologically identical to erythema nodosum secondary to other causes [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/13\">",
"     13",
"    </a>",
"    ]. Sarcoidosis is a relatively common cause of EN; in a Spanish study of 106 biopsy proven cases of EN, 20 percent of patients had sarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with EN develop erythematous, tender, subcutaneous plaques and nodules predominantly located on the anterior tibial areas (",
"    <a class=\"graphic graphic_picture graphicRef76621 graphicRef55744 \" href=\"UTD.htm?37/11/38072\">",
"     picture 20A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/34\">",
"     34",
"    </a>",
"    ]. Arthritis, lower extremity edema, and low grade fever are the most common systemic symptoms associated with EN. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13130?source=see_link\">",
"     \"Erythema nodosum\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    EN is a transient disorder. In a case series that included 251 patients with sarcoidosis-associated EN, over 85 percent had complete resolution within two years [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/102\">",
"     102",
"    </a>",
"    ]. In addition, EN has been associated with a favorable prognosis for sarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/102,103\">",
"     102,103",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13130?source=see_link&amp;anchor=H16#H16\">",
"     \"Erythema nodosum\", section on 'Sarcoidosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical features of subcutaneous sarcoidosis can resemble erythema nodosum [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/104\">",
"     104",
"    </a>",
"    ]. Biopsy is useful for distinguishing between these disorders. Histopathologic findings in EN are consistent with a septal panniculitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18191936\">",
"    <span class=\"h3\">",
"     L&ouml;fgren&rsquo;s syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;L&ouml;fgren&rsquo;s syndrome is an acute presentation of sarcoidosis characterized by the triad of hilar adenopathy, erythema nodosum, and polyarthralgia or arthritis, with or without parenchymal infiltrates or fever. More recently, the definition has been expanded to include patients with hilar adenopathy and periarticular inflammation with or without erythema nodosum. [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/105-107\">",
"     105-107",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/12/11463?source=see_link\">",
"     \"Sarcoid arthropathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=see_link&amp;anchor=H23#H23\">",
"     \"Clinical manifestations and diagnosis of sarcoidosis\", section on 'Lofgren's syndrome'",
"    </a>",
"    .)",
"    <br/>",
"   </p>",
"   <p>",
"    The presence of bilateral hilar adenopathy and erythema nodosum is usually, but not always, caused by acute sarcoidosis. This presentation has also been reported in tuberculosis, lymphoma, streptococcal infection, histoplasmosis, coccidiomycosis, and Chlamydia pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/108,109\">",
"     108,109",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13130?source=see_link\">",
"     \"Erythema nodosum\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18191957\">",
"    <span class=\"h1\">",
"     PEDIATRIC SARCOIDOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cutaneous involvement may be more common in the pediatric population than in adults. The skin may be involved in approximately 80 percent of children younger than five years of age with sarcoidosis and between 24 and 40 percent of older children with sarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/110\">",
"     110",
"    </a>",
"    ]. The most common specific eruptions are papular, consisting of red to yellow-brown or violaceous flat-topped papules, usually on the face. However, the entire spectrum of clinical cutaneous sarcoidosis has been described in children [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/111\">",
"     111",
"    </a>",
"    ]. In a retrospective study of 46 children with sarcoidosis (mean age of presentation 14 years), 10 (22 percent) had erythema nodosum, 10 had unspecified skin sarcoidosis, and 3 (7 percent) exhibited sarcoidosis involving scar tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/112\">",
"     112",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18191964\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;According to a consensus statement on sarcoidosis from the American Thoracic Society, the European Respiratory Society, and the World Association of Sarcoidosis and Other Granulomatous Disorders, the diagnosis of sarcoidosis requires a compatible clinical picture, the demonstration of noncaseating granulomas on tissue biopsy, and the exclusion of other disorders that can present with similar clinical and histopathologic findings [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/113\">",
"     113",
"    </a>",
"    ]. The skin is easily accessible, and a biopsy of a specific cutaneous lesion of sarcoidosis is a simple and safe method of obtaining a tissue specimen. Thus, recognition of lesions of cutaneous sarcoidosis can be highly valuable in patients with symptoms or radiologic findings that are suggestive of systemic disease.",
"   </p>",
"   <p>",
"    The detection of noncaseating granulomas in the skin is not sufficient to confirm a diagnosis of sarcoidosis in the absence of evidence for other organ involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/113\">",
"     113",
"    </a>",
"    ]. However, the identification of lesions that are clinically and histopathologically consistent with cutaneous sarcoidosis is useful for identifying patients who may benefit from further evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1174376\">",
"    <span class=\"h2\">",
"     Examination and biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of cutaneous sarcoidosis is supported by the identification of lesions that are morphologically compatible with sarcoidosis, the detection of sarcoidal granulomas on histopathologic examination, and the exclusion of other disorders in the differential diagnosis.",
"   </p>",
"   <p>",
"    Clinical examination of the skin is the first step towards confirming a diagnosis of cutaneous sarcoidosis. Diascopy, a procedure that involves compressing a skin lesion with a clear glass microscope slide, is a simple method for detecting cutaneous granulomatous disorders on clinical examination. In granulomatous conditions, diascopy often reveals a subtle, brown-yellow or &ldquo;apple jelly&rdquo; color during lesion compression. This sign is most appreciable in individuals with light skin pigmentation. Diascopy is not a specific test for sarcoidosis, and other granulomatous disorders can exhibit similar findings.",
"   </p>",
"   <p>",
"    In lesions that are clinically suspicious for sarcoidosis, a skin biopsy should be performed to look for histopathologic features that are consistent with the diagnosis. Although noncaseating granulomas with sparse, peripheral lymphocytic infiltrates are characteristic of sarcoidosis, similar histopathologic features may be seen in other disorders, and not all lesions of sarcoidosis demonstrate classic findings [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/114\">",
"     114",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H245206\">",
"     'Histopathology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Biopsy specimens should be examined under polarized light to evaluate for the presence of refractile material that could indicate granuloma formation secondary to a foreign body reaction. In addition, tissue staining for acid fast bacilli and fungi, microbial cultures of fresh tissue, and tuberculin skin testing should be performed if clinical or histopathologic features suggest the possibility of mycobacterial or deep fungal infections [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/20,76,115\">",
"     20,76,115",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1174383\">",
"    <span class=\"h2\">",
"     Evaluation for systemic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the patient presenting with cutaneous lesions that are clinically and histopathologically consistent with sarcoidosis, the following work-up for systemic disease should be performed [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/116-118\">",
"     116-118",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Focused patient history and review of systems",
"     </li>",
"     <li>",
"      Complete physical examination",
"     </li>",
"     <li>",
"      Posterior and anterior chest radiography",
"     </li>",
"     <li>",
"      Pulmonary function tests including diffusing capacity studies (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=see_link\">",
"       \"Overview of pulmonary function testing in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/27/29112?source=see_link\">",
"       \"Overview of pulmonary function testing in children\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Electrocardiogram",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15924?source=see_link\">",
"       Tuberculin skin test",
"      </a>",
"      or interferon-gamma release assay for latent tuberculosis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20648?source=see_link\">",
"       \"Diagnosis of latent tuberculosis infection in HIV-negative adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37160?source=see_link\">",
"       \"Interferon-gamma release assays for diagnosis of latent tuberculosis infection\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Ophthalmologic examination",
"     </li>",
"     <li>",
"      Laboratory studies (complete blood count (CBC), serum calcium, hepatitic transaminases, alkaline phosphatase, blood urea nitrogen (BUN), serum creatinine, urinalysis, baseline serum angiotensin converting enzyme level)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1174390\">",
"    <span class=\"h2\">",
"     Other tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of serum angiotensin converting enzyme (ACE) level is often considered in patients who present with signs or symptoms suggestive of sarcoidosis. However, ACE levels are nonspecific for the diagnosis of sarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/7\">",
"     7",
"    </a>",
"    ]. ACE levels are sometimes used for following the response to treatment in patients with systemic sarcoidosis; the value of the test for this indication remains unclear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=see_link&amp;anchor=H33#H33\">",
"     \"Clinical manifestations and diagnosis of sarcoidosis\", section on 'Serum ACE'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other markers, such as serum lysozyme, neopterin, and osteopontin that can be elevated in the presence of granulomatous disease are even less specific than ACE levels for the diagnosis of sarcoidosis, and are unlikely to be elevated in patients in whom the disease burden is limited to the skin [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/119\">",
"     119",
"    </a>",
"    ]. Laboratory abnormalities such as leukopenia, anemia, eosinophilia, and hypercalcemia are rare in the absence of systemic disease.",
"   </p>",
"   <p>",
"    Historically, the Kveim-Siltzbach test was used in the diagnosis of sarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/45\">",
"     45",
"    </a>",
"    ]. The test involves the injection of spleen extract from an individual with systemic sarcoidosis into the dermis of patients with signs or symptoms suggestive of sarcoidosis. The injection site is subsequently biopsied to assess for the formation of granulomas. In one series of 127 patients with cutaneous sarcoidosis, 38 percent had a positive Kveim test six weeks after injection [",
"    <a class=\"abstract\" href=\"UTD.htm?19/20/19786/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Due to poor standardization of the test, concern about transfer of viral infections, and unavailability of the substrate in many countries, the Kveim-Siltzbach test is rarely performed in the clinical setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/24/20866?source=see_link\">",
"       \"Patient information: Erythema nodosum (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18191978\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sarcoidosis is a granulomatous disease that can affect one or more organs. Cutaneous involvement occurs in up to 25 percent of patients. (See",
"      <a class=\"local\" href=\"#H5344750\">",
"       'Epidemiology and classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pathogenesis of cutaneous sarcoidosis is not well understood. A combination of genetic and environmental factors may contribute an aberrant immune response and granuloma formation. (See",
"      <a class=\"local\" href=\"#H18191762\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Specific lesions of sarcoidosis classically demonstrate noncaseating granulomas with sparse peripheral lymphocytic infiltrates on biopsy. Asteroid bodies or Schaumann bodies may be visible in giant cells within the granulomas. Foreign body reactions, mycobacterial infections, and fungal infections are among the disorders that should be considered in the histopathologic differential diagnosis. (See",
"      <a class=\"local\" href=\"#H245206\">",
"       'Histopathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The morphology of cutaneous lesions of sarcoidosis is variable. Examples of specific skin manifestations of sarcoidosis include papules, nodules, plaques, and atrophic or ulcerative lesions. The risk of the development of systemic sarcoidosis in patients who present with disease limited to the skin is unknown. (See",
"      <a class=\"local\" href=\"#H18191778\">",
"       'Clinical manifestations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H245665\">",
"       'Association with systemic disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lupus pernio is a distinct variant of cutaneous sarcoidosis that presents with violaceous or erythematous papules, plaques, or nodules predominantly involving the central facial skin. The nasal alae are often affected. Patients with lupus pernio appear to have an increased risk for sarcoidosis involving the respiratory tract. (See",
"      <a class=\"local\" href=\"#H18191808\">",
"       'Lupus pernio'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The development of sarcoidosis in a scar or tattoo site may be the initial sign of sarcoidosis in some patients. Lesions may occur up to decades after the initial injury or tattoo. Clinicians should be aware of the possibility of sarcoidosis in patients with a changing or persistently inflammatory scar. (See",
"      <a class=\"local\" href=\"#H797331\">",
"       'Scar sarcoidosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H797338\">",
"       'Tattoo sarcoidosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Erythema nodosum is the most common nonspecific manifestation of sarcoidosis. Patients usually present with inflammatory plaques or nodules involving the lower legs. Biopsy is useful for distinguishing erythema nodosum from subcutaneous sarcoidosis. Development of erythema nodosum is associated with a favorable prognosis for sarcoidosis with increased disease resolution. (See",
"      <a class=\"local\" href=\"#H18191929\">",
"       'Erythema nodosum'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13130?source=see_link&amp;anchor=H16#H16\">",
"       \"Erythema nodosum\", section on 'Sarcoidosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Diascopy is a useful test to identify signs of granulomatous disease during clinical examination. A skin biopsy should be performed to confirm the diagnosis of cutaneous sarcoidosis. Specimens should be examined under polarized light to look for evidence for foreign bodies. Stains of biopsied tissue and exudate and tissue cultures should be performed when clinical or histologic findings suggest the possibility of mycobacterial or deep fungal infections. (See",
"      <a class=\"local\" href=\"#H18191964\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with cutaneous sarcoidosis should be evaluated for the possibility of systemic disease. Testing should include a complete physical exam, chest x-ray, pulmonary function test, electrocardiogram, tuberculin skin testing, a urinalysis, and several blood studies. (See",
"      <a class=\"local\" href=\"#H1174383\">",
"       'Evaluation for systemic disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/1\">",
"      Ma&ntilde;&aacute; J, Marcoval J, Graells J, et al. Cutaneous involvement in sarcoidosis. Relationship to systemic disease. Arch Dermatol 1997; 133:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/2\">",
"      Hanno R, Needelman A, Eiferman RA, Callen JP. Cutaneous sarcoidal granulomas and the development of systemic sarcoidosis. Arch Dermatol 1981; 117:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/3\">",
"      English JC 3rd, Patel PJ, Greer KE. Sarcoidosis. J Am Acad Dermatol 2001; 44:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/4\">",
"      Samtsov AV. Cutaneous sarcoidosis. Int J Dermatol 1992; 31:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/5\">",
"      Mangas C, Fern&aacute;ndez-Figueras MT, Fit&eacute; E, et al. Clinical spectrum and histological analysis of 32 cases of specific cutaneous sarcoidosis. J Cutan Pathol 2006; 33:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/6\">",
"      Elgart MD. Skin manifestations of sarcoidosis. Cutis 1965; 1:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/7\">",
"      Lodha S, Sanchez M, Prystowsky S. Sarcoidosis of the skin: a review for the pulmonologist. Chest 2009; 136:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/8\">",
"      Krasowska D, Schwartz RA, Wojnowska D, et al. Polymorphous cutaneous and chronic multisystem sarcoidosis. Acta Dermatovenerol Alp Panonica Adriat 2008; 17:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/9\">",
"      Rapp SE. An unusual cause of hair loss. Arch Dermatol 2002; 138:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/10\">",
"      Marcoval J, Ma&ntilde;&aacute; J, Moreno A, et al. Foreign bodies in granulomatous cutaneous lesions of patients with systemic sarcoidosis. Arch Dermatol 2001; 137:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/11\">",
"      Yanarda H, Pamuk ON, Karayel T. Cutaneous involvement in sarcoidosis: analysis of the features in 170 patients. Respir Med 2003; 97:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/12\">",
"      Ben Jennet S, Benmously R, Cha&acirc;bane S, et al. [Cutaneous sarcoidosis through a hospital series of 28 cases]. Tunis Med 2008; 86:447.",
"     </a>",
"    </li>",
"    <li>",
"     Lynch PJ, Sams WM Jr. Principles and practice of dermatology, Churchill Livingstone Inc., New York 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/14\">",
"      Elgart ML. Cutaneous sarcoidosis: definitions and types of lesions. Clin Dermatol 1986; 4:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/15\">",
"      Zaba LC, Smith GP, Sanchez M, Prystowsky SD. Dendritic cells in the pathogenesis of sarcoidosis. Am J Respir Cell Mol Biol 2010; 42:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/16\">",
"      Ali MM, Atwan AA, Gonzalez ML. Cutaneous sarcoidosis: updates in the pathogenesis. J Eur Acad Dermatol Venereol 2010; 24:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/17\">",
"      Kim YC, Triffet MK, Gibson LE. Foreign bodies in sarcoidosis. Am J Dermatopathol 2000; 22:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/18\">",
"      Derler AM, Eisendle K, Baltaci M, et al. High prevalence of 'Borrelia-like' organisms in skin biopsies of sarcoidosis patients from Western Austria. J Cutan Pathol 2009; 36:1262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/19\">",
"      Lassalle S, Selva E, Hofman V, et al. Sarcoid-like lesions associated with the immune restoration inflammatory syndrome in AIDS: absence of polymerase chain reaction detection of Mycobacterium tuberculosis in granulomas isolated by laser capture microdissection. Virchows Arch 2006; 449:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/20\">",
"      Ball NJ, Kho GT, Martinka M. The histologic spectrum of cutaneous sarcoidosis: a study of twenty-eight cases. J Cutan Pathol 2004; 31:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/21\">",
"      Walsh NM, Hanly JG, Tremaine R, Murray S. Cutaneous sarcoidosis and foreign bodies. Am J Dermatopathol 1993; 15:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/22\">",
"      Batres E, Klima M, Tschen J. Transepithelial elimination in cutaneous sarcoidosis. J Cutan Pathol 1982; 9:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/23\">",
"      Callen JP. The presence of foreign bodies does not exclude the diagnosis of sarcoidosis. Arch Dermatol 2001; 137:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/24\">",
"      Alexis JB. Sarcoidosis presenting as cutaneous hypopigmentation with repeatedly negative skin biopsies. Int J Dermatol 1994; 33:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/25\">",
"      Shirodaria CC, Nicholson AG, Hansell DM, et al. Lesson of the month: Necrotizing sarcoid granulomatosis with skin involvement. Histopathology 2003; 43:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/26\">",
"      Rosen Y, Moon S, Huang CT, et al. Granulomatous pulmonary angiitis in sarcoidosis. Arch Pathol Lab Med 1977; 101:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/27\">",
"      Magro CM, Crowson AN, Regauer S. Granuloma annulare and necrobiosis lipoidica tissue reactions as a manifestation of systemic disease. Hum Pathol 1996; 27:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/28\">",
"      Goldberg LJ, Goldberg N, Abrahams I, et al. Giant cell lichenoid dermatitis: a possible manifestation of sarcoidosis. J Cutan Pathol 1994; 21:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/29\">",
"      Cardoso JC, Cravo M, Reis JP, Tellechea O. Cutaneous sarcoidosis: a histopathological study. J Eur Acad Dermatol Venereol 2009; 23:678.",
"     </a>",
"    </li>",
"    <li>",
"     Ko, CJ, Glusac, EJ, Shapiro, PE. Noninfectious granulomas. In: Lever's Histopathology of the Skin, 10th edition, Elder, DE (Eds), Lippincott Williams &amp; Wilkins, 2009. p.361.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/31\">",
"      Terushkin V, Stern BJ, Judson MA, et al. Neurosarcoidosis: presentations and management. Neurologist 2010; 16:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/32\">",
"      Kim JS, Judson MA, Donnino R, et al. Cardiac sarcoidosis. Am Heart J 2009; 157:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/33\">",
"      Haimovic A, Sanchez M, Judson MA, Prystowsky S. Sarcoidosis: a comprehensive review and update for the dermatologist: part I. Cutaneous disease. J Am Acad Dermatol 2012; 66:699.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/34\">",
"      Katta R. Cutaneous sarcoidosis: a dermatologic masquerader. Am Fam Physician 2002; 65:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/35\">",
"      Mahajan VK, Sharma NL, Sharma RC, Sharma VC. Cutaneous sarcoidosis: clinical profile of 23 Indian patients. Indian J Dermatol Venereol Leprol 2007; 73:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/36\">",
"      Okamoto H, Horio T, Izumi T. Micropapular sarcoidosis simulating lichen nitidus. Dermatologica 1985; 170:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/37\">",
"      Beacham BE, Schuldenfrei J, Julka SS. Sarcoidosis presenting with erythema multiforme-like cutaneous lesions. Cutis 1984; 33:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/38\">",
"      Dumitrescu SM, Schwartz RA, Baredes S, et al. Mutilating facial sarcoidosis. Dermatology 1999; 199:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/39\">",
"      Leonard AL. A case of sarcoidosis mimicking rhinophyma. J Drugs Dermatol 2003; 2:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/40\">",
"      Ahmed I, Harshad SR. Subcutaneous sarcoidosis: is it a specific subset of cutaneous sarcoidosis frequently associated with systemic disease? J Am Acad Dermatol 2006; 54:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/41\">",
"      MAYOCK RL, BERTRAND P, MORRISON CE, SCOTT JH. MANIFESTATIONS OF SARCOIDOSIS. ANALYSIS OF 145 PATIENTS, WITH A REVIEW OF NINE SERIES SELECTED FROM THE LITERATURE. Am J Med 1963; 35:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/42\">",
"      Vainsencher D, Winkelmann RK. Subcutaneous sarcoidosis. Arch Dermatol 1984; 120:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/43\">",
"      Rodriguez-Gomez M, Fernandez-Sueiro JL, Willisch A, et al. Multifocal dactylitis as the sole clinical expression of sarcoidosis. J Rheumatol 2000; 27:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/44\">",
"      Jacyk WK. Cutaneous sarcoidosis in black South Africans. Int J Dermatol 1999; 38:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/45\">",
"      Veien NK, Stahl D, Brodthagen H. Cutaneous sarcoidosis in Caucasians. J Am Acad Dermatol 1987; 16:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/46\">",
"      Young RJ 3rd, Gilson RT, Yanase D, Elston DM. Cutaneous sarcoidosis. Int J Dermatol 2001; 40:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/47\">",
"      Aubart FC, Ouayoun M, Brauner M, et al. Sinonasal involvement in sarcoidosis: a case-control study of 20 patients. Medicine (Baltimore) 2006; 85:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/48\">",
"      Jorizzo JL, Koufman JA, Thompson JN, et al. Sarcoidosis of the upper respiratory tract in patients with nasal rim lesions: a pilot study. J Am Acad Dermatol 1990; 22:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/49\">",
"      Spiteri MA, Matthey F, Gordon T, et al. Lupus pernio: a clinico-radiological study of thirty-five cases. Br J Dermatol 1985; 112:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/50\">",
"      Terunuma A, Watabe A, Kato T, Tagami H. Coexistence of vitiligo and sarcoidosis in a patient with circulating autoantibodies. Int J Dermatol 2000; 39:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/51\">",
"      Albertini JG, Tyler W, Miller OF 3rd. Ulcerative sarcoidosis. Case report and review of the literature. Arch Dermatol 1997; 133:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/52\">",
"      Yoo SS, Mimouni D, Nikolskaia OV, et al. Clinicopathologic features of ulcerative-atrophic sarcoidosis. Int J Dermatol 2004; 43:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/53\">",
"      Burov EA, Kantor GR, Isaac M. Morpheaform sarcoidosis: report of three cases. J Am Acad Dermatol 1998; 39:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/54\">",
"      Hess SP, Agudelo CA, White WL, Jorizzo JL. Ichthyosiform and morpheaform sarcoidosis. Clin Exp Rheumatol 1990; 8:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/55\">",
"      Huang CL, Mutasim DF. Sarcoidosis mimicking lipodermatosclerosis. Cutis 2005; 75:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/56\">",
"      Arias-Santiago S, Santiago SA, Fern&aacute;ndez-Pugnaire MA, et al. Recurrent telangiectasias on the cheek: angiolupoid sarcoidosis. Am J Med 2010; 123:e7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/57\">",
"      Glass LA, Apisarnthanarax P. Verrucous sarcoidosis simulating hypertrophic lichen planus. Int J Dermatol 1989; 28:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/58\">",
"      Ko R, Tanaka M, Murata T, Nishikawa T. Papular fixed drug eruption mimicking folliculitis due to acetominophen. Clin Exp Dermatol 2000; 25:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/59\">",
"      Cather JC, Cohen PR. Ichthyosiform sarcoidosis. J Am Acad Dermatol 1999; 40:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/60\">",
"      Banse-Kupin L, Pelachyk JM. Ichthyosiform sarcoidosis. Report of two cases and a review of the literature. J Am Acad Dermatol 1987; 17:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/61\">",
"      Feind-Koopmans AG, Lucker GP, van de Kerkhof PC. Acquired ichthyosiform erythroderma and sarcoidosis. J Am Acad Dermatol 1996; 35:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/62\">",
"      ZHANG H, MA HJ, LIU W, YUAN XY. Sarcoidosis characterized as acquired ichthyosiform erythroderma. Eur J Dermatol 2009; 19:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/63\">",
"      Greer KE, Harman LE Jr, Kayne AL. Unusual cutaneous manifestations of sarcoidosis. South Med J 1977; 70:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/64\">",
"      Wirth FA, Gould WM, Kauffman CL. Erythroderma in a patient with arthralgias, uveitis, and dyspnea. Arch Dermatol 1999; 135:1411, 1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/65\">",
"      Bazex J, Dupin P, Giordano F. [Cutaneous and visceral sarcoidosis. Apropos of an exceptional form]. Ann Dermatol Venereol 1987; 114:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/66\">",
"      Morrison JG. Sarcoidosis in a child, presenting as an erythroderma with keratotic spines and palmar pits. Br J Dermatol 1976; 95:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/67\">",
"      Yoon CH, Lee CW. Case 6. Erythrodermic form of cutaneous sarcoidosis. Clin Exp Dermatol 2003; 28:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/68\">",
"      Truchot F, Skowron F, Grande S, et al. [Photo-induced sarcoidosis]. Ann Dermatol Venereol 2003; 130:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/69\">",
"      Macdonald J, Southgate HJ. Lessons to be learned: a case study approach. Sunshine-induced hypercalcaemia? J R Soc Promot Health 2002; 122:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/70\">",
"      MOSER HS, SOLOWEY CM, LEIDER M. An unusual form of cutaneous sarcoidosis. N Y State J Med 1962; 62:1859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/71\">",
"      Norton SA, Chesser RS, Fitzpatrick JE. Scar sarcoidosis in pseudofolliculitis barbae. Mil Med 1991; 156:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/72\">",
"      Cecchi R, Giomi A. Scar sarcoidosis following herpes zoster. J Eur Acad Dermatol Venereol 1999; 12:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/73\">",
"      Kormeili T, Neel V, Moy RL. Cutaneous sarcoidosis at sites of previous laser surgery. Cutis 2004; 73:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/74\">",
"      Payne CM, Thomas RH, Black MM. From silica granuloma to scar sarcoidosis. Clin Exp Dermatol 1983; 8:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/75\">",
"      JAMES DG. Dermatological aspects of sarcoidosis. Q J Med 1959; 28:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/76\">",
"      Chudomirova K, Velichkova L, Anavi B, Arnaudova M. Recurrent sarcoidosis in skin scars accompanying systemic sarcoidosis. J Eur Acad Dermatol Venereol 2003; 17:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/77\">",
"      Sorabjee JS, Garje R. Reactivation of old scars: inevitably sarcoid. Postgrad Med J 2005; 81:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/78\">",
"      Antonovich DD, Callen JP. Development of sarcoidosis in cosmetic tattoos. Arch Dermatol 2005; 141:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/79\">",
"      Katta R, Nelson B, Chen D, Roenigk H. Sarcoidosis of the scalp: a case series and review of the literature. J Am Acad Dermatol 2000; 42:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/80\">",
"      Henderson CL, Lafleur L, Sontheimer RD. Sarcoidal alopecia as a mimic of discoid lupus erythematosus. J Am Acad Dermatol 2008; 59:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/81\">",
"      Mann RJ, Allen BR. Nail dystrophy due to sarcoidosis. Br J Dermatol 1981; 105:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/82\">",
"      Davies MG, McGavin CR. Onycholysis in sarcoidosis--a previously undescribed association. Br J Dermatol 1996; 135:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/83\">",
"      Fujii K, Kanno Y, Ohgo N. Subungual hyperkeratosis due to sarcoidosis. Int J Dermatol 1997; 36:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/84\">",
"      Kalb RE, Grossman ME. Pterygium formation due to sarcoidosis. Arch Dermatol 1985; 121:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/85\">",
"      Aranegui B, Garcia-Cruz A, de la Torre C, Gonz&aacute;lez-Valladares MG. Trachyonychia and sarcoidosis. J Am Acad Dermatol 2010; 63:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/86\">",
"      Losada-Campa A, De la Torre-Fraga C, Gomez de Lia&ntilde;o A, Cruces-Prado MJ. Histopathology of nail sarcoidosis. Acta Derm Venereol 1995; 75:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/87\">",
"      Cox NH, Gawkrodger DJ. Nail dystrophy in chronic sarcoidosis. Br J Dermatol 1988; 118:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/88\">",
"      Santoro F, Sloan SB. Nail dystrophy and bony involvement in chronic sarcoidosis. J Am Acad Dermatol 2009; 60:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/89\">",
"      Ezughah FI, Ghaly AF, Evans A, Green CM. Vulval sarcoid: a systemic presentation of sarcoidosis. J Obstet Gynaecol 2005; 25:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/90\">",
"      Tatnall FM, Barnes HM, Sarkany I. Sarcoidosis of the vulva. Clin Exp Dermatol 1985; 10:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/91\">",
"      de Oliveira Neto MP. [Sarcoidosis with vulvar lesions]. Rev Bras Med 1972; 29:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/92\">",
"      Friedman KA, Rudikoff D. Multiple indurated papules on penis and scrotum. J Cutan Med Surg 2000; 4:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/93\">",
"      Mahmood N, Afzal N, Joyce A. Sarcoidosis of the penis. Br J Urol 1997; 80:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/94\">",
"      Rubinstein I, Baum GL, Hiss Y. Sarcoidosis of the penis: report of a case. J Urol 1986; 135:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/95\">",
"      Vahid B, Weibel S, Nguyen C. Scrotal swelling and sarcoidosis. Am J Med 2006; 119:e3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/96\">",
"      HAUSFELD KF. Primary sarcoidosis of the scrotum: case report. J Urol 1961; 86:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/97\">",
"      Suresh L, Radfar L. Oral sarcoidosis: a review of literature. Oral Dis 2005; 11:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/98\">",
"      Blinder D, Yahatom R, Taicher S. Oral manifestations of sarcoidosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997; 83:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/99\">",
"      Jackowski J, Dragisic D, Arnold G, Dirschka T. Primary oral sarcoidosis preceding Lofgren's syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005; 100:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/100\">",
"      Kowalczyk JP, Ricotti CA, de Araujo T, et al. \"Strawberry gums\" in sarcoidosis. J Am Acad Dermatol 2008; 59:S118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/101\">",
"      Garc&iacute;a-Porr&uacute;a C, Gonz&aacute;lez-Gay MA, V&aacute;zquez-Caruncho M, et al. Erythema nodosum: etiologic and predictive factors in a defined population. Arthritis Rheum 2000; 43:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/102\">",
"      Neville E, Walker AN, James DG. Prognostic factors predicting the outcome of sarcoidosis: an analysis of 818 patients. Q J Med 1983; 52:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/103\">",
"      Milman N, Selroos O. Pulmonary sarcoidosis in the Nordic countries 1950-1982. II. Course and prognosis. Sarcoidosis 1990; 7:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/104\">",
"      Okamoto H, Mizuno K, Imamura S, et al. Erythema nodosum-like eruption in sarcoidosis. Clin Exp Dermatol 1994; 19:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/105\">",
"      Grunewald J, Eklund A. Sex-specific manifestations of L&ouml;fgren's syndrome. Am J Respir Crit Care Med 2007; 175:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/106\">",
"      Ma&ntilde;&aacute; J, G&oacute;mez-Vaquero C, Montero A, et al. L&ouml;fgren's syndrome revisited: a study of 186 patients. Am J Med 1999; 107:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/107\">",
"      Grunewald J, Eklund A. L&ouml;fgren's syndrome: human leukocyte antigen strongly influences the disease course. Am J Respir Crit Care Med 2009; 179:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/108\">",
"      L&ouml;fgren S. Erythema nodosum: study on etiology and pathogenesis in 185 adult cases. Acta Med Scand 1946; suppl 174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/109\">",
"      Marie I, Lecomte F, Levesque H, et al. L&ouml;fgren's syndrome as the first manifestation of acute infection due to Chlamydia pneumoniae: a prospective study. Clin Infect Dis 1999; 28:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/110\">",
"      James DG, Kendig EL Jr. Childhood sarcoidosis. Sarcoidosis 1988; 5:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/111\">",
"      Hetherington S. Sarcoidosis in young children. Am J Dis Child 1982; 136:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/112\">",
"      Milman N, Hoffmann AL. Childhood sarcoidosis: long-term follow-up. Eur Respir J 2008; 31:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/113\">",
"      Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999; 160:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/114\">",
"      Miida H, Ito M. Tuberculoid granulomas in cutaneous sarcoidosis: a study of 49 cases. J Cutan Pathol 2010; 37:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/115\">",
"      Moss J, Zic J, Drake W. Mycobacterial infection masquerading as cutaneous sarcoidosis. Clin Exp Dermatol 2009; 34:e199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/116\">",
"      Costabel U, Hunninghake GW. ATS/ERS/WASOG statement on sarcoidosis. Sarcoidosis Statement Committee. American Thoracic Society. European Respiratory Society. World Association for Sarcoidosis and Other Granulomatous Disorders. Eur Respir J 1999; 14:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/117\">",
"      Newman LS, Rose CS, Maier LA. Sarcoidosis. N Engl J Med 1997; 336:1224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/118\">",
"      Haimovic A, Sanchez M, Judson MA, Prystowsky S. Sarcoidosis: a comprehensive review and update for the dermatologist: part II. Extracutaneous disease. J Am Acad Dermatol 2012; 66:719.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/20/19786/abstract/119\">",
"      M&uuml;ller-Quernheim J. Sarcoidosis: immunopathogenetic concepts and their clinical application. Eur Respir J 1998; 12:716.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13762 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-190.111.122.2-14B9D587E9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_20_19786=[""].join("\n");
var outline_f19_20_19786=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18191978\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18191748\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5344750\">",
"      EPIDEMIOLOGY AND CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18191762\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H245206\">",
"      HISTOPATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5641743\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H245665\">",
"      ASSOCIATION WITH SYSTEMIC DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18191778\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18191794\">",
"      Papular sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6092903\">",
"      Nodular sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29997403\">",
"      - Subcutaneous sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2494193\">",
"      Maculopapular sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18191801\">",
"      Plaque sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18191808\">",
"      Lupus pernio",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H797125\">",
"      Hypopigmented sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18191815\">",
"      Atrophic and ulcerative sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H630708\">",
"      Rare variants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18191822\">",
"      - Angiolupoid sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18191829\">",
"      - Psoriasiform sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18191850\">",
"      - Verrucous sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18191864\">",
"      - Ichthyosiform sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18191871\">",
"      - Erythrodermic sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2494761\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H244886\">",
"      SARCOIDOSIS OF SPECIAL SITES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H797331\">",
"      Scar sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H797338\">",
"      Tattoo sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18191906\">",
"      Alopecia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18191913\">",
"      Nail sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H244631\">",
"      Genital sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H244638\">",
"      Sarcoidosis of the oral cavity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18191920\">",
"      NONSPECIFIC ERUPTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18191929\">",
"      Erythema nodosum",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18191936\">",
"      - L&ouml;fgren&rsquo;s syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18191957\">",
"      PEDIATRIC SARCOIDOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18191964\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1174376\">",
"      Examination and biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1174383\">",
"      Evaluation for systemic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1174390\">",
"      Other tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18191978\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/13762\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13762|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/41/3736\" title=\"picture 1A\">",
"      Cutaneous sarcoidosis - histopathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/63/1017\" title=\"picture 1B\">",
"      Cutaneous sarcoidosis - histopathology high power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/30/15844\" title=\"picture 2A\">",
"      Papular sarcoidosis - face",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/31/32244\" title=\"picture 2B\">",
"      Sarcoidosis - facial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/62/19426\" title=\"picture 3\">",
"      Sarcoidosis resembling lichen nitidus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/5/22612\" title=\"picture 4\">",
"      Nodular sarcoidosis - rhinophymatous",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/45/22225\" title=\"picture 5\">",
"      Subcutaneous sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/5/13396\" title=\"picture 6\">",
"      Maculopapular sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/49/8978\" title=\"picture 7A\">",
"      Plaque sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/1/4115\" title=\"picture 7B\">",
"      Plaque sarcoidosis - annular",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/5/34898\" title=\"picture 8A\">",
"      Lupus pernio - nasal tip",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/25/32148\" title=\"picture 8B\">",
"      Lupus pernio - nose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/63/33776\" title=\"picture 9A\">",
"      Hypopigmented sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/34/10791\" title=\"picture 9B\">",
"      Hypopigmented sarcoidosis - close view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/55/11121\" title=\"picture 10\">",
"      Ulcerative sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/34/22052\" title=\"picture 11A\">",
"      Angiolupoid sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/1/18449\" title=\"picture 11B\">",
"      Angiolupoid sarcoidosis - cheek",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/5/2133\" title=\"picture 12\">",
"      Psoriasiform sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/9/40085\" title=\"picture 13\">",
"      Verrucous sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/3/31807\" title=\"picture 14\">",
"      Ichthyosiform sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/1/30739\" title=\"picture 15A\">",
"      Erythrodermic sarcoidosis - chest",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/25/36244\" title=\"picture 15B\">",
"      Erythrodermic sarcoidosis - flank",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/10/13481\" title=\"picture 16\">",
"      Tattoo sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/25/26005\" title=\"picture 17\">",
"      Sarcoidosis alopecia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/12/18626\" title=\"picture 18\">",
"      Nail sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/40/3713\" title=\"picture 19\">",
"      Sarcoidosis of the lip",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/59/12209\" title=\"picture 20A\">",
"      Erythema nodosum - legs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/29/7638\" title=\"picture 20B\">",
"      Erythema nodosum - close view",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=related_link\">",
"      Clinical manifestations and diagnosis of sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20648?source=related_link\">",
"      Diagnosis of latent tuberculosis infection in HIV-negative adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13130?source=related_link\">",
"      Erythema nodosum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37160?source=related_link\">",
"      Interferon-gamma release assays for diagnosis of latent tuberculosis infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/8/16522?source=related_link\">",
"      Management of cutaneous sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=related_link\">",
"      Overview of pulmonary function testing in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/27/29112?source=related_link\">",
"      Overview of pulmonary function testing in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6376?source=related_link\">",
"      Pathogenesis of sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/24/20866?source=related_link\">",
"      Patient information: Erythema nodosum (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/12/11463?source=related_link\">",
"      Sarcoid arthropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38074?source=related_link\">",
"      Treatment of pulmonary sarcoidosis with alternatives to glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/43/11961?source=related_link\">",
"      Treatment of pulmonary sarcoidosis with glucocorticoids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_20_19787="Steroidogenic enzymes";
var content_f19_20_19787=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F55287&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F55287&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Nomenclature used for steroidogenic enzymes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        New gene symbol",
"       </td>",
"       <td class=\"subtitle1\">",
"        Prior designation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Trivial name",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CYP11A1",
"       </td>",
"       <td>",
"        P450scc",
"       </td>",
"       <td>",
"        Cholesterol side chain cleavage enzyme; desmolase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3&beta;-hydroxysteroid dehydrogenase II",
"       </td>",
"       <td>",
"        3&beta;-hydroxysteroid dehydrogenase",
"       </td>",
"       <td>",
"        3&beta;-hydroxysteroid dehydrogenase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CYP17",
"       </td>",
"       <td>",
"        P450c17",
"       </td>",
"       <td>",
"        17 alpha-hydroxylase/17, 20-lyase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CYP21A2",
"       </td>",
"       <td>",
"        P450c21",
"       </td>",
"       <td>",
"        21-hydroxylase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CYP11B1",
"       </td>",
"       <td>",
"        P450c11",
"       </td>",
"       <td>",
"        11&beta;-hydroxylase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CYP11B2",
"       </td>",
"       <td>",
"        P450c11as",
"       </td>",
"       <td>",
"        Aldosterone synthase, corticosterone methyl oxidase",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_20_19787=[""].join("\n");
var outline_f19_20_19787=null;
var title_f19_20_19788="Metabolic syndrome definitions in children and adolescents";
var content_f19_20_19788=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F66120&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F66120&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Definitions of metabolic syndrome in children and adolescents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Parameters",
"       </td>",
"       <td class=\"subtitle1\">",
"        Modified ATP III",
"       </td>",
"       <td class=\"subtitle1\">",
"        IDF (10 to 16 years)",
"       </td>",
"       <td class=\"subtitle1\">",
"        NHANES III",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Required",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Waist circumference",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &ge;90th percentile*",
"       </td>",
"       <td>",
"        &ge;90th percentile",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Number of abnormalities",
"       </td>",
"       <td>",
"        &ge;3",
"       </td>",
"       <td>",
"        &ge;2",
"       </td>",
"       <td>",
"        All",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Triglyceride",
"       </td>",
"       <td>",
"        &gt;95th percentile",
"       </td>",
"       <td>",
"        &ge;150 mg/dL (1.7 mmol/L)",
"       </td>",
"       <td>",
"        &ge;110 mg/dL (1.24 mmol/L)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        HDL",
"       </td>",
"       <td>",
"        &lt;5th percentile",
"       </td>",
"       <td>",
"        &lt;40 mg/dL (1.03 mmol/L)",
"       </td>",
"       <td>",
"        &le;40 mg/dL (1.03 mmol/L)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        BP",
"       </td>",
"       <td>",
"        Either",
"       </td>",
"       <td>",
"        Either",
"       </td>",
"       <td rowspan=\"3\">",
"        &ge;90th percentile",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Systolic",
"       </td>",
"       <td>",
"        &gt;95th percentile",
"       </td>",
"       <td>",
"        &gt;130 mmHg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Diastolic",
"       </td>",
"       <td>",
"        &gt;95th percentile",
"       </td>",
"       <td>",
"        &ge;85 mmHg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Glucose",
"       </td>",
"       <td>",
"        Impaired glucose tolerance",
"       </td>",
"       <td>",
"        &ge;100 mg/dL (5.6 mmol/L)",
"       </td>",
"       <td>",
"        Fasting &ge;110 mg/dL (6.1 mmol/L)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ATP III: Adult Treatment Panel; IDF: International Diabetes Federation; NHANES: National Health and Nutrition Examination Survey; HDL: high-density lipoprotein; BP: blood pressure.",
"     <br>",
"      * Ethnic-specific waist circumference (see Fernandez JR, Redden DT, Pietrobelli A, et al. Waist circumference percentiles in nationally representative samples of African-American, European-American, and Mexican-American children and adolescents. J Pediatr 2004; 145:439).",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_20_19788=[""].join("\n");
var outline_f19_20_19788=null;
var title_f19_20_19789="2002 AJCC staging CRC CA";
var content_f19_20_19789=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F56205&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F56205&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    TNM staging system for colorectal cancer, 6th edition",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Primary tumor (T)*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tis",
"       </td>",
"       <td colspan=\"3\">",
"        Carcinoma in situ; intraepithelial (within glandular basement membrane) or invasion of lamina propria (intramucosal)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T1",
"       </td>",
"       <td colspan=\"3\">",
"        Tumor invades submucosa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T2",
"       </td>",
"       <td colspan=\"3\">",
"        Tumor invades muscularis propria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T3",
"       </td>",
"       <td colspan=\"3\">",
"        Tumor invades through the muscularis propria into the subserosa, or into non-peritonealized pericolic or perirectal tissues",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T4",
"       </td>",
"       <td colspan=\"3\">",
"        Tumor directly invades other organs or structures, and/or perforates visceral peritoneum&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Regional lymph node (N)&Delta;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        NX",
"       </td>",
"       <td colspan=\"3\">",
"        Regional nodes cannot be assessed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        N0",
"       </td>",
"       <td colspan=\"3\">",
"        No regional nodal metastases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        N1",
"       </td>",
"       <td colspan=\"3\">",
"        Metastasis in 1 to 3 regional lymph nodes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        N2",
"       </td>",
"       <td colspan=\"3\">",
"        Metastasis in 4 or more regional lymph nodes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Distant metastasis (M)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MX",
"       </td>",
"       <td colspan=\"3\">",
"        Distant metastasis cannot be assessed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        M0",
"       </td>",
"       <td colspan=\"3\">",
"        No distant metastasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        M1",
"       </td>",
"       <td colspan=\"3\">",
"        Distant metastasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Stage groupings&loz;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"\">",
"        Stage 0",
"       </td>",
"       <td>",
"        Tis",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"\">",
"        Stage I",
"       </td>",
"       <td>",
"        T1-2",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"\">",
"        Stage IIA",
"       </td>",
"       <td>",
"        T3",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"\">",
"        Stage IIB",
"       </td>",
"       <td>",
"        T4",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"\">",
"        Stage IIIA",
"       </td>",
"       <td>",
"        T1-2",
"       </td>",
"       <td>",
"        N1",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"\">",
"        Stage IIIB",
"       </td>",
"       <td>",
"        T3-4",
"       </td>",
"       <td>",
"        N1",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"\">",
"        Stage IIIC",
"       </td>",
"       <td>",
"        Any T",
"       </td>",
"       <td>",
"        N2",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"\">",
"        Stage IV",
"       </td>",
"       <td>",
"        Any T",
"       </td>",
"       <td>",
"        Any N",
"       </td>",
"       <td>",
"        M1",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The completeness of resection of the primary tumor should be reflected by designation of the radial margin status (the surgically dissected surface adjacent to the deepest point of tumor invasion beyond the wall of the large bowel). R0: complete tumor resection, with all margins negative; R1: incomplete tumor resection with microscopic margin involvement; R2: incomplete tumor resection with gross residual tumor that was not resected.",
"     <br>",
"      &bull; Direct invasion in T4 includes invasion of other segments of the colorectum by way of the serosa. Tumor that is adherent to other organs or structures, macroscopically, is classified T4. However, if no tumor is present in the adhesion, the classification should be pT3. V and L substaging should used to denote the presence or absence of vascular or lymphatic invasion.",
"      <br>",
"       &Delta; A tumor nodule in the pericolorectal adipose tissue of a primary carcinoma without histologic evidence of residual lymph node in the nodule is classified as a regional nodal metastasis if the nodule has the form and smooth contour of a lymph node. If it has an irregular contour, it should be classified in the T category, and also coded as V1 (microscopic venous invasion) or V2 (if it was grossly evident), because of the strong likelihood that it represents venous invasion.",
"       <br>",
"        &loz; The y prefix is used for those cancers that are classified following treatment, whereas the r prefix is used for recurrent cancers.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Sixth Edition (2002) published by Springer-Verlag New York, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_20_19789=[""].join("\n");
var outline_f19_20_19789=null;
var title_f19_20_19790="Desens 12step 250mL";
var content_f19_20_19790=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F52381&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F52381&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Example of 12-step desensitization protocol for 2000 mg of ceftazidime (250 mL per solution)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Solution",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Total volume",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Concentration",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Solution 1",
"       </td>",
"       <td colspan=\"2\">",
"        250 mL",
"       </td>",
"       <td colspan=\"2\">",
"        0.080 mg/mL",
"       </td>",
"       <td colspan=\"2\">",
"        20 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Solution 2",
"       </td>",
"       <td colspan=\"2\">",
"        250 mL",
"       </td>",
"       <td colspan=\"2\">",
"        0.800 mg/mL",
"       </td>",
"       <td colspan=\"2\">",
"        200 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Solution 3",
"       </td>",
"       <td colspan=\"2\">",
"        250 mL",
"       </td>",
"       <td colspan=\"2\">",
"        7.937 mg/mL",
"       </td>",
"       <td colspan=\"2\">",
"        2000 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Step",
"       </td>",
"       <td class=\"subtitle1\">",
"        Solution",
"       </td>",
"       <td class=\"subtitle1\">",
"        Rate (mL/hour)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Time (minute)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Volume infused per step (mL)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose administered with this step (mg)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cumulative dose (mg)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2.0",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        0.50",
"       </td>",
"       <td>",
"        0.040",
"       </td>",
"       <td>",
"        0.040",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        5.0",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        1.25",
"       </td>",
"       <td>",
"        0.100",
"       </td>",
"       <td>",
"        0.140",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        10.0",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        2.50",
"       </td>",
"       <td>",
"        0.200",
"       </td>",
"       <td>",
"        0.340",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        20.0",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        5.00",
"       </td>",
"       <td>",
"        0.400",
"       </td>",
"       <td>",
"        0.740",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        5.0",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        1.25",
"       </td>",
"       <td>",
"        1.000",
"       </td>",
"       <td>",
"        1.740",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        10.0",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        2.50",
"       </td>",
"       <td>",
"        2.000",
"       </td>",
"       <td>",
"        3.740",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        20.0",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        5.00",
"       </td>",
"       <td>",
"        4.000",
"       </td>",
"       <td>",
"        7.740",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        40.0",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        10.00",
"       </td>",
"       <td>",
"        8.000",
"       </td>",
"       <td>",
"        15.740",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        10.0",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        2.50",
"       </td>",
"       <td>",
"        19.843",
"       </td>",
"       <td>",
"        35.583",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        20.0",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        5.00",
"       </td>",
"       <td>",
"        39.685",
"       </td>",
"       <td>",
"        75.268",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        40.0",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        10.00",
"       </td>",
"       <td>",
"        79.370",
"       </td>",
"       <td>",
"        154.638",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        80.0",
"       </td>",
"       <td>",
"        174.375",
"       </td>",
"       <td>",
"        232.50",
"       </td>",
"       <td>",
"        1845.362",
"       </td>",
"       <td>",
"        2000.000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"7\">",
"        <strong>",
"         NOTE:",
"        </strong>",
"        Each step is administered over 15 minutes. At conclusion of protocol, observe patient for 30 minutes, then give full therapeutic dose by the desired route.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"7\">",
"        Total time = 339.37 minutes (5 hours 39 minutes).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        Desensitization protocol instructions:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"7\">",
"        1. Confirm written consent is in medical record.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"7\">",
"        2. Please ensure preceding dose of beta-blockers was held, unless otherwise advised by supervising clinician.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"7\">",
"        3. Obtain IV access, and vital signs (temperature, HR, BP, RR, oxygen saturation, peak flow).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"7\">",
"        4. Have at bedside: Epinephrine 0.3 mg (for adult) for IM injection, oxygen, normal saline, peak flow meter, and BP cuff, albulterol, injectable preparation of diphenhydramine , and methylprednisolone.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"7\">",
"        5. A nurse must closely observe the patient throughout the protocol (one-to-one).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"7\">",
"        <strong>",
"         Administration:",
"        </strong>",
"        Hang each solution successively. Each step is administered over 15 minutes, per protocol. There is no reason to wait between bags. Vital signs should be taken and recorded every 15 minutes, and every 30 minutes during the last step.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        Monitoring and charting during desensitization:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"7\">",
"        Please clearly document any reaction, including:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\" colspan=\"7\">",
"        a. Patient's symptoms, vital signs, and physical findings;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\" colspan=\"7\">",
"        b. Exactly when the reaction occurred (ie, what step, how many minutes into that step);",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\" colspan=\"7\">",
"        c. Treatment administered, how and when the reaction resolved, and when the protocol was restarted.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        Treatment of allergic reactions:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"7\">",
"        <strong>",
"         For mild reactions:",
"        </strong>",
"        In case of isolated itching, flushing, hives, mild chest tightness, nausea, abdominal pain, or back pain, with normal vital signs, stop the infusion and treat with IV diphenhydramine. Observe patient until the reaction subsides, and then resume the protocol by repeating the step at which the reaction occurred.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"7\">",
"        <strong>",
"         For severe reactions:",
"        </strong>",
"        In case of hypotension, throat swelling, wheezing/respiratory distress, or decreased oxygen saturation, stop the infusion and treat with epinephrine 0.3 mg IM x 1, diphenhydramine and methylprednisolone IV, oxygen, inhaled albuterol for bronchospasm, and IV fluids (normal saline). Place patient in a recumbent position if hypotensive. Consider glucagon 1 to 2 mg IV bolus if patient has taken beta-blockers, followed by infusion at 1 to 5 mg/hour.",
"        <strong>",
"         Immediately alert the housestaff and supervising&nbsp;clinician.",
"        </strong>",
"        When the patient is stable, the protocol will be resumed as instructed by the supervising clinician.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"7\">",
"        <strong>",
"         Contact the supervising&nbsp;clinician for ANY severe or prolonged reaction, or any questions regarding the protocol, reactions, and appropriate management.",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Legere HJ 3rd, Palis RI, Bouza TR, et al. A safe protocol for rapid desensitization in patients with cystic fibrosis and antibiotic hypersensitivity. J Cyst Fibros 2009; 8:418. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"     <br>",
"      Instructions courtesy of Mariana Castells, MD, PhD.",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_20_19790=[""].join("\n");
var outline_f19_20_19790=null;
var title_f19_20_19791="Contents: Parasitic infections";
var content_f19_20_19791=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?15/21/15710\">",
"       Infectious Diseases",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Parasitic infections",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Parasitic infections",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Antiparasitic drugs",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/43/23221\">",
"           Anthelminthic therapies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/59/17335\">",
"           Antiprotozoal therapies",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         General",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/10/24745\">",
"           Approach to the patient with eosinophilia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/2/27688\">",
"           Causes of pulmonary eosinophilia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/24/30090\">",
"           Clinical manifestations, pathophysiology, and diagnosis of the hypereosinophilic syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/52/23361\">",
"           Clinical microbiology review: Blood and tissue parasites",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/37/40535\">",
"           Diseases with eosinophilic involvement of specific organs",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/43/40632\">",
"           Eosinophilic meningitis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Helminths &mdash; Cestodes (tapeworms)",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/36/28232\">",
"           Clinical manifestations and diagnosis of cysticercosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/23/28025\">",
"           Clinical manifestations and diagnosis of echinococcosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/59/20407\">",
"           Epidemiology and control of echinococcosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/3/15413\">",
"           Epidemiology, transmission and prevention of cysticercosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/26/4519\">",
"           Intestinal tapeworms",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/28/17865\">",
"           Treatment of cysticercosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/58/27561\">",
"           Treatment of echinococcosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Helminths &mdash; Nematodes (roundworms)",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/8/16520\">",
"           Ascariasis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/24/36229\">",
"           Cutaneous larva migrans (creeping eruption)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/56/15241\">",
"           Diagnosis, treatment, and prevention of lymphatic filariasis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/33/2583\">",
"           Enterobiasis and trichuriasis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/25/13719\">",
"           Epidemiology, pathogenesis, and clinical manifestations of lymphatic filariasis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/28/42437\">",
"           Hookworm infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/26/36263\">",
"           Loiasis (Loa loa infection)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/17/5398\">",
"           Mansonella infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/8/44168\">",
"           Miscellaneous nematodes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/30/20970\">",
"           Onchocerciasis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/25/11668\">",
"           Pulmonary manifestations of ascariasis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/59/11193\">",
"           Strongyloidiasis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/34/16935\">",
"           Toxocariasis: visceral and ocular larva migrans",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/54/15207\">",
"           Trichinellosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/30/2532\">",
"           Tropical filarial pulmonary eosinophilia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Helminths &mdash; Trematodes (flukes)",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/14/7398\">",
"           Diagnosis of schistosomiasis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/38/15977\">",
"           Epidemiology, pathogenesis, and clinical features of schistosomiasis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/3/14389\">",
"           Intestinal flukes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/25/10648\">",
"           Liver flukes: Clonorchiasis and opisthorchiasis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/63/31735\">",
"           Liver flukes: Fascioliasis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/40/14985\">",
"           Noncirrhotic portal hypertension: Portal fibrosis and schistosomiasis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/6/36967\">",
"           Paragonimiasis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/28/34243\">",
"           Schistosomiasis and glomerular disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/29/14807\">",
"           Treatment and prevention of schistosomiasis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Protozoa &mdash; Amebiasis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/16/33031\">",
"           Extraintestinal Entamoeba histolytica amebiasis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/56/33671\">",
"           Intestinal Entamoeba histolytica amebiasis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Protozoa &mdash; Babesiosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/25/39321\">",
"           Clinical manifestations, diagnosis, treatment, and prevention of babesiosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/16/42248\">",
"           Epidemiology and pathogenesis of babesiosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Protozoa &mdash; General",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/4/32834\">",
"           Balantidium coli infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/14/39143\">",
"           Blastocystis species",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/58/36773\">",
"           Clinical management of patients with Cystoisospora infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/48/31493\">",
"           Cyclospora infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/26/35237\">",
"           Dientamoeba fragilis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/44/30405\">",
"           Epidemiology, clinical manifestations, and diagnosis of Cystoisospora infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/40/13961\">",
"           Epidemiology, clinical manifestations, and diagnosis of cryptosporidiosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/28/33224\">",
"           Epidemiology, clinical manifestations, and diagnosis of giardiasis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/41/4762\">",
"           Free-living amebas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/45/16089\">",
"           Microsporidiosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/0/10243\">",
"           Nonpathogenic enteric protozoa",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/40/1670\">",
"           Treatment and prevention of cryptosporidiosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/17/6424\">",
"           Treatment and prevention of giardiasis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Protozoa &mdash; Leishmaniasis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/42/21161\">",
"           Clinical manifestations and diagnosis of visceral leishmaniasis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/15/23797\">",
"           Epidemiology and control of cutaneous leishmaniasis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/20/42308\">",
"           Epidemiology and control of visceral leishmaniasis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/18/33063\">",
"           Epidemiology, clinical manifestations and diagnosis of cutaneous leishmaniasis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/51/26426\">",
"           Treatment and prevention of cutaneous leishmaniasis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/38/43625\">",
"           Treatment of visceral leishmaniasis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Protozoa &mdash; Malaria",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/18/19754\">",
"           Anemia in malaria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/26/5543\">",
"           Clinical manifestations of malaria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/0/10248\">",
"           Diagnosis of malaria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/5/16473\">",
"           Epidemiology, prevention, and control of malaria in endemic areas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/8/3209\">",
"           HIV and malaria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/30/23011\">",
"           Mosquito vectors of infectious diseases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/33/16921\">",
"           Overview of malaria in pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/18/4394\">",
"           Overview of non-falciparum malaria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/1/39959\">",
"           Pathogenesis of malaria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/3/13370\">",
"           Prevention of malaria infection in travelers",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/0/24585\">",
"           Protection against malaria by abnormalities in red cell surface antigens and cytoskeletal proteins",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/23/20858\">",
"           Protection against malaria in the hemoglobinopathies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/13/20695\">",
"           Treatment and prevention of malaria in pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/1/13338\">",
"           Treatment of severe falciparum malaria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/41/25241\">",
"           Treatment of uncomplicated falciparum malaria",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Protozoa &mdash; Toxoplasmosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/6/19559\">",
"           Diagnostic assays for toxoplasmosis infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/24/28041\">",
"           Overview of TORCH infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/39/22137\">",
"           Toxoplasmosis and pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/22/33129\">",
"           Toxoplasmosis in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/38/16999\">",
"           Toxoplasmosis in immunocompetent hosts",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Protozoa &mdash; Trypanosomiasis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/1/14356\">",
"           Antitrypanosomal drug therapy for Chagas disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/57/2969\">",
"           Chagas disease: Management of acute disease, early chronic disease, and disease in immunocompromised hosts",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/34/551\">",
"           Chagas disease: Natural history and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/59/14266\">",
"           Clinical manifestations and diagnosis of Chagas heart disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/49/38681\">",
"           Clinical manifestations, diagnosis, and treatment of African trypanosomiasis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/20/23880\">",
"           Epidemiology and control of Chagas disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/36/13895\">",
"           Epidemiology, pathogenesis, and prevention of African trypanosomiasis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/22/16742\">",
"           Gastrointestinal Chagas disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/32/19975\">",
"           Pathology and pathogenesis of Chagas disease",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-CBA90C306F-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f19_20_19791=[""].join("\n");
var outline_f19_20_19791=null;
